

**BUKTI
SUBMIT
MANUSKRIP**

Submission Confirmation

1 message

International Journal of Pharmaceutics <em@editorialmanager.com>
Reply-To: International Journal of Pharmaceutics <support@elsevier.com>
To: Andi Dian Permana <andi.dian.permana@farmasi.unhas.ac.id>

Sun, Sep 4, 2022 at 9:08 PM

Re: Enhanced skin localization of metronidazole using solid lipid microparticles incorporated into polymeric hydrogels for potential improved of rosaceae treatment

Research Paper

Sulistiawati Sulistiawati; Kadek Saka Dwipayanti; Muhammad Azhar; Achmad Himawan; Andi Dian Permana

Dear Dr. Permana,

Your submission entitled "Enhanced skin localization of metronidazole using solid lipid microparticles incorporated into polymeric hydrogels for potential improved of rosaceae treatment" has been received by International Journal of Pharmaceutics

You may check on the progress of your paper by logging on to the Editorial Manager as an author. The URL is <https://www.editorialmanager.com/ijpharm/>.

Your username is: andipermana

If you need to retrieve password details, please go to: <https://www.editorialmanager.com/ijpharm/l.asp?i=773920&l=2A1EGB31>

Your manuscript will be given a reference number once an Editor has been assigned.

Thank you for submitting your work to this journal.

IJP is the 2nd most cited journal in the category "Pharmacy & Pharmacology" (out of 279 journals) (Clarivate 2022).

IJPX is the open access companion journal of IJP. It received its first impact factor this year: 5.679.

Both journals are the true home for pharmaceutical scientists concerned with the physical, chemical and biological properties of devices and delivery systems for drugs, vaccines and biologicals, including their design, manufacture and evaluation.

Kind regards,

Editorial Manager
International Journal of Pharmaceutics

For further assistance, please visit our customer support site at <http://help.elsevier.com/app/answers/list/p/7923>. Here you can search for solutions on a range of topics, find answers to frequently asked questions and learn more about EM via interactive tutorials. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

This journal uses the Elsevier Article Transfer Service. This means that if an editor feels your manuscript is more suitable for an alternative journal, then you might be asked to consider transferring the manuscript to such a journal. The recommendation might be provided by a Journal Editor, a dedicated Scientific Managing Editor, a tool assisted recommendation, or a combination. For more details see the journal guide for authors.

#AU_IJPHARM#

To ensure this email reaches the intended recipient, please do not delete the above code

In compliance with data protection regulations, you may request that we remove your personal registration details at

any time. (Use the following URL: <https://www.editorialmanager.com/ijpharm/login.asp?a=r>). Please contact the publication office if you have any questions.

**BUKTI
REVIEW
DARI
REVIEWERS**



Andi Dian Permana <andi.dian.permana@farmasi.unhas.ac.id>

Your Submission IJPHARM-D-22-02381

1 message

International Journal of Pharmaceutics <em@editorialmanager.com>
Reply-To: International Journal of Pharmaceutics <support@elsevier.com>
To: Andi Dian Permana <andi.dian.permana@farmasi.unhas.ac.id>

Fri, Oct 7, 2022 at 6:05 PM

Ms. Ref. No.: IJPHARM-D-22-02381

Title: Enhanced skin localization of metronidazole using solid lipid microparticles incorporated into polymeric hydrogels for potential improved of rosaceae treatment
International Journal of Pharmaceutics

Dear Dr. Permana,

Comments on your paper have now been received and are attached to this message. Please consider all the points made and upon returning your paper detail your responses and the actions taken.

Please submit the revised manuscript by Dec 06, 2022. Upon receipt of your revised paper, we will inform you of the outcome as soon as possible. Papers not received within that that time period will be considered to be withdrawn, you are welcome to resubmit your paper as a new submission at a later date.

NOTE: While submitting the revised manuscript, please double check the author names provided in the submission so that authorship related changes are made in the revision stage. If your manuscript is accepted, any authorship change will involve approval from co-authors and respective editor handling the submission and this may cause a significant delay in publishing your manuscript.

PLEASE NOTE: International Journal of Pharmaceutics would like to invite you to enrich your article by including a list of up to 10 names of chemical compounds studied in the article.

Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here: <https://www.elsevier.com/authors/author-services/data-visualization> to find out about available data visualization options and how to include them with your article.

Thank you for submitting your work to the journal.

Research Elements (optional)

This journal encourages you to share research objects - including your raw data, methods, protocols, software, hardware and more – which support your original research article in a Research Elements journal. Research Elements are open access, multidisciplinary, peer-reviewed journals which make the objects associated with your research more discoverable, trustworthy and promote replicability and reproducibility. As open access journals, there may be an Article Publishing Charge if your paper is accepted for publication. Find out more about the Research Elements journals at https://www.elsevier.com/authors/tools-and-resources/research-elements-journals?dgcid=ec_em_research_elements_email.

Yours sincerely,

Abdul W Basit, PhD
Editor
International Journal of Pharmaceutics

p.s. To submit a revision, please go to <https://www.editorialmanager.com/IJPHARM> and login as an Author.

Your username is: andipermana

If you need to retrieve password details, please go to: <https://www.editorialmanager.com/ijpharm/l.asp?i=788573&I=LQQ05OUJ>

On your Main Menu page is a folder entitled "Submissions Needing Revision". You will find your submission record there.

Reviewers' comments:

Reviewer #1: Dear respected editor

The manuscript entitled "Enhanced skin localization of metronidazole using solid lipid 1 microparticles incorporated into polymeric hydrogels for potential improved of rosaceae treatment" described the preparation and characterization of metronidazole loaded solid lipid microparticles.

The manuscript is interesting; however several points should be considered for accepting the manuscript.

Minor points are listed below:

- 1- First of all the manuscript should be checked by an English native speaker to remove the syntax and typos; in addition some sentences are very long
- 2- One of the major shortcomings of the manuscript is that it does not refer in the introduction part such literature data in which metronidazole have been formulated topically using different delivery systems to treat rosaceae.
- 3- The novelty of the work should be clearly stated, other articles with similar work had been published: "Metronidazole-loaded nanostructured lipid carriers to improve skin deposition and retention in the treatment of rosacea, Drug Dev Ind Pharm, 2019 Jul;45(7):1039-1051."
- 4- SLMs containing metronidazole had been prepared using other methods of preparation, The authors should justify the choice of this method used in the preparation of SLMs,
- 5- How did the authors measure the entrapment efficiency without separating the free drug?
- 6- What is the ratio of SLMs to gel used to obtain the final preparation?
- 7- Please correct the decimal of the numbers in Table 1, and add asterisk symbol to show the significance
- 8- Figure 4 should be corrected by drawing the shear rate on the x axis and the shear stress on the y axis

Major point

It is regrettable that the authors do not carry out in vitro and in vivo study to test the antioxidant effect, anti-inflammatory effect and the safety of the prepared formula, especially there are organic solvent included in the preparation.

%ATTACH_FOR_REVIEWER_DEEP_LINK INSTRUCTIONS%

For further assistance, please visit our customer support site at <http://help.elsevier.com/app/answers/list/p/7923>. Here you can search for solutions on a range of topics, find answers to frequently asked questions and learn more about EM via interactive tutorials. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

#AU_IJPHARM#

To ensure this email reaches the intended recipient, please do not delete the above code

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/ijpharm/login.asp?a=r>). Please contact the publication office if you have any questions.

**BUKTI
SUBMIT
HASIL
REVIEW**



Andi Dian Permana <andi.dian.permana@farmasi.unhas.ac.id>

Submission Confirmation for IJPHARM-D-22-02381R1

1 message

International Journal of Pharmaceutics <em@editorialmanager.com>
Reply-To: International Journal of Pharmaceutics <support@elsevier.com>
To: Andi Dian Permana <andi.dian.permana@farmasi.unhas.ac.id>

Sun, Oct 16, 2022 at 8:16 PM

Ms. Ref. No.: IJPHARM-D-22-02381R1

Title: Enhanced skin localization of metronidazole using solid lipid microparticles incorporated into polymeric hydrogels for potential improved of rosacea treatment: An ex vivo proof of concept investigation
International Journal of Pharmaceutics

Dear Dr. Permana,

Your revised manuscript was received for reconsideration for publication in International Journal of Pharmaceutics.

You may check the status of your manuscript by logging onto the Editorial Manager as an Author at
<https://www.editorialmanager.com/ijpharm/>.

Your username is: andipermana

If you need to retrieve password details, please go to: <https://www.editorialmanager.com/ijpharm/l.asp?i=792265&I=TB85JZIV>

IJP is the 2nd most cited journal in the category "Pharmacy & Pharmacology" (out of 279 journals) (Clarivate 2022).

IJPX is the open access companion journal of IJP. It received its first impact factor this year: 5.679.

Both journals are the true home for pharmaceutical scientists concerned with the physical, chemical and biological properties of devices and delivery systems for drugs, vaccines and biologicals, including their design, manufacture and evaluation.

Kind regards,

Editorial Manager
International Journal of Pharmaceutics

For further assistance, please visit our customer support site at <http://help.elsevier.com/app/answers/list/p/7923>. Here you can search for solutions on a range of topics, find answers to frequently asked questions and learn more about EM via interactive tutorials. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

#AU_IJPHARM#

To ensure this email reaches the intended recipient, please do not delete the above code

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/ijpharm/login.asp?a=r>). Please contact the publication office if you have any questions.

International Journal of Pharmaceutics

Enhanced skin localization of metronidazole using solid lipid microparticles incorporated into polymeric hydrogels for potential improved of rosacea treatment: An ex vivo proof of concept investigation

--Manuscript Draft--

Manuscript Number:	IJPHARM-D-22-02381R1
Article Type:	Research Paper
Section/Category:	
Keywords:	Rosacea; metronidazole; solid lipid microparticles; hydrogel
Corresponding Author:	Andi Dian Permana, Ph.D Hasanuddin University Makassar, INDONESIA
First Author:	Sulistiawati Sulistiawati
Order of Authors:	Sulistiawati Sulistiawati Kadek Saka Dwipayanti Muhammad Azhar Latifah Rahman Ermina Pakki Achmad Himawan Andi Dian Permana, Ph.D
Abstract:	<p>Metronidazole (MNZ) is a nitroimidazole derivative antibiotic that has been generally used in the treatment of rosacea. However, it has low molecular weight and lipophilicity, limiting the effectiveness of MNZ in the topical treatment of rosacea. This study reports an MNZ-loaded solid lipid microparticle (SLM) gel formulation with sustained drug release effects required in the treatment of rosacea. SLM was formulated using the double emulsification method with five different concentrations of glyceryl monostearate (GMS) as a solid lipid used to encapsulate MNZ. All the MNZ-loaded SLM formulas were extensively characterized by various analytical tools. After optimized MNZ-loaded SLM formulation was obtained, then formulated into gel preparation. To obtain a gel formula with good physical characteristics and drug release in the development of topical therapy, the SLM-loaded gel was further evaluated, covering various parameters such as pH, viscosity, rheology, spreadability, extrudability, skin occlusivity, gel strength, permeation and retention ex vivo, as well as hemolysis tests and antioxidant activity. The evaluation results showed that the SLM formulations had desired properties with optimum encapsulation efficiency. Moreover, the gels prepared from carbomer possessed desired characteristics and were found to be hemocompatible. In addition, the gel formula with a carbomer concentration of 1.25% can provide better drug release with the highest MNZ retention after 24 hours of 2.35 ± 0.05 mg. Notably, the formulation of MNZ into SLM and hydrogel did not affect the antioxidant activity. Thus, it can provide continuous drug release, which could potentially be useful in increasing efficacy in rosacea therapy. The results obtained also showed a significant difference ($p < 0.05$) compared to the control formula and other formulas. Therefore, this study has proven a new approach to developing drug delivery systems for rosacea treatment.</p>

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

1 **Enhanced skin localization of metronidazole using solid lipid microparticles incorporated**
2 **into polymeric hydrogels for potential improved of rosacea treatment: *An ex vivo* proof**
3 **of concept investigation**

4 Sulistiawati, Kadek Saka Dwipayanti, Muhammad Azhar, **Latifah Rahman, Ermina Pakki,**
5 Achmad Himawan, Andi Dian Permana*

6 *Faculty of Pharmacy, Hasanuddin University, Makassar, 90245, Indonesia*

7 *Corresponding author:

8 Andi Dian Permana

9 Faculty of Pharmacy, Hasanuddin University, Indonesia

10 Email: andi.dian.permana@farmasi.unhas.ac.id

11

12

13

14

15

16

17

18

19

20

21

22

23

24 **ABSTRACT**

25 Metronidazole (MNZ) is a nitroimidazole derivative antibiotic that has been generally used in
26 the treatment of rosacea. However, it has low molecular weight and lipophilicity, limiting the
27 effectiveness of MNZ in the topical treatment of rosacea. This study reports an MNZ-loaded
28 solid lipid microparticle (SLM) gel formulation with sustained drug release effects required in
29 the treatment of rosacea. SLM was formulated using the double emulsification method with
30 five different concentrations of glyceryl monostearate (GMS) as a solid lipid used to
31 encapsulate MNZ. All the MNZ-loaded SLM formulas were extensively characterized by
32 various analytical tools. After optimized MNZ-loaded SLM formulation was obtained, then
33 formulated into gel preparation. To obtain a gel formula with good physical characteristics and
34 drug release in the development of topical therapy, the SLM-loaded gel was further evaluated,
35 covering various parameters such as pH, viscosity, rheology, spreadability, extrudability, skin
36 occlusivity, gel strength, permeation and retention ex vivo, as well as hemolysis tests and
37 antioxidant activity. The evaluation results showed that the SLM formulations had desired
38 properties with optimum encapsulation efficiency. Moreover, the gels prepared from carbomer
39 possessed desired characteristics and were found to be hemocompatible. In addition, the gel
40 formula with a carbomer concentration of 1.25% can provide better drug release with the
41 highest MNZ retention after 24 hours of 2.35 ± 0.05 mg. Notably, the formulation of MNZ into
42 SLM and hydrogel did not affect the antioxidant activity. Thus, it can provide continuous drug
43 release, which could potentially be useful in increasing efficacy in rosacea therapy. The results
44 obtained also showed a significant difference ($p < 0.05$) compared to the control formula and
45 other formulas. Therefore, this study has proven a new approach to developing drug delivery
46 systems for rosacea treatment.

47 **Keywords:** Rosacea; metronidazole; solid lipid microparticles; hydrogel

48
49
50
51
52
53
54
55
56
57

58 1. INTRODUCTION

59 Rosacea is a chronic inflammatory condition that occurs in the skin, especially the
60 centofacial area (nose, cheeks, chin, and forehead) that affects blood vessels and sebaceous
61 glands (Gonçalves and De Pina, 2017; van Zuuren et al., 2021). This disorder has various risk
62 factors such as environmental, microbial infection, immune dysfunction, and genetics, but the
63 pathophysiology and pathogenesis are not known with certainty (Engin et al., 2017; Rainer et
64 al., 2019; Zhang et al., 2021). Rosacea can affect anyone, but it is more common in people
65 between the ages of 30 and 60, as well as those with Fitzpatrick skin types I-III (Gonçalves and
66 De Pina, 2017; Jabbehdari et al., 2021). In addition, rosacea is also more prone to occur in
67 women than in men, with a ratio of 1.7:1 (Jabbehdari et al., 2021).

68 The principle of rosacea treatment is to avoid the causative factors and reduce
69 inflammation. One of the main treatments that has been widely used to treat this disease is
70 using antibiotics such as metronidazole (MNZ) (Engin et al., 2017; Weiss and Katta, 2017).
71 MNZ is a nitroimidazole-derived antibiotic that works by inhibiting the growth of various
72 bacteria and parasites (Ceruelos et al., 2019). MNZ has advantages over other antibiotics,
73 making it the most commonly used antibiotic in the last 50 years due to its low drug resistance,
74 well-established safety profile, and negligible adverse response (Miyachi et al., 2022; Tran et
75 al., 2019). In addition, MNZ is known to treat the inflammation in rosacea through anti-
76 inflammatory and immunomodulatory pathways that work against inflammatory lesions
77 (papules and pustules) (Miyachi et al., 2022). This skin condition that occurs in someone who
78 has rosacea is also very closely related to the presence of reactive oxygen species (ROS). MNZ
79 also has antioxidant properties resulting from neutrophil modulation and acts as a scavenger
80 (Berth-Jones et al., 2020; Miyachi et al., 2022).

81 Various therapies that can be used in the treatment of rosacea include oral, topical,
82 injection, laser, and light-based therapies, treatments for certain types of rosacea, and
83 treatments for systemic comorbidities. However, oral and topical therapies are more often used
84 for the treatment of the early stages of rosacea disease (Zhang et al., 2021). MNZ is a class I
85 BCS drug which causes MNZ, when given orally, to be more easily absorbed and more easily
86 eliminated, resulting in reduced bioavailability and is considered less effective in the treatment
87 of rosacea (Yu et al., 2014; Zhang et al., 2019). Treatment of MNZ by oral route may also pose
88 a risk of peripheral neuropathy (Hajariwala et al., 2021). Therefore, MNZ via the topical route
89 is considered to be much more effective in delivering the active substance to the target site for
90 an extended period (Kaur and Guleri, 2013).

91 MNZ has a low molecular weight of 171.15 g/mol and a log p -1.18. Thus, when applied
92 topically to the skin surface, this drug can penetrate the skin but has a low retention time (Yu
93 et al., 2014). Therefore, it is necessary to control the release of the drug to increase its retention
94 time in the skin without releasing it directly into the system. Several approaches have been
95 developed to improve the skin delivery of MNZ, including nanostructured lipid carrier (Shinde
96 et al., 2019) and nanoemulsion (Yu et al., 2014). However, despite the fact that the formulations
97 could improve the transdermal delivery of MNZ, in the rosacea treatment, it is crucial to retain
98 the drug in the skin layers. It has been previously reported that compared to nanoparticles,
99 microparticle systems possessed better skin retention profiles (Permana et al., 2021a).
100 Accordingly, it was hypothesized that the incorporation of MNZ into the microparticle system
101 could improve the skin retention of MNZ. One of the formulations that can be developed is
102 solid lipid microparticles (SLM). SLM is a drug delivery system that is suitable for various
103 routes, especially through the topical route, because it has low toxicity characteristics, is
104 physiologically compatible, biodegradable, occlusive, and has controlled release properties to
105 increase the bioavailability of the active substance (De Caro et al., 2021; Nahum and Domb,
106 2021; Rahimpour et al., 2016). In addition, SLM can also provide better solubilization and
107 dispersion of active ingredients and can be produced on a large scale at low costs (Nahum and
108 Domb, 2021). Then, to facilitate the administration of SLM, the selection of topical dosage
109 forms needs to be considered. One of the topical dosage forms that can be used is gel.

110 When compared with other topical preparations, such as creams and ointments, gels can
111 provide better application and stability properties (Patil et al., 2019). Based on research
112 conducted by Rahimpour et al., (2016), the release of tetracycline HCl through SLM, which
113 was made in the form of a gel dosage form, showed a controlled drug release pattern. Ex vivo
114 studies also showed that there was an increase in dermal deposition of tetracycline HCl up to
115 7 times that of the control formula. Therefore, the gel dosage form was considered as the most
116 suitable system to deliver MNZ.

117 The gel in its formulation requires a gelling agent that functions as a gelling agent.
118 Carbomer 940 is a strong gelling agent, so it only takes a small concentration to form a gel
119 (Rowe et al., 2009). In addition, compared to other gelling agents, carbomer 940 is a polymer
120 with superior drug release compared to other polymers and is non-toxic, biocompatible, and
121 non-irritating (Patel et al., 2011; Zhang et al., 2020). Based on previous research conducted by
122 Yen et al. (2015), on the use of carbomers in controlling the release of galantamine, it was
123 found that the gelling agent was able to control the release of galantamine by 2 times with an
124 increase in the amount of carbomer concentration used. To the best of our knowledge, this is

125 the first study developing SLM loaded hydrogel to enhance the skin localization of MNZ. In
126 this study, we formulated SLM using glyceryl monostearate (GMS) as a lipid matrix.
127 Furthermore, the SLMs were incorporated into the carbomer-based hydrogel. A proof of
128 concept was carried out in *an ex vivo* study. The results of this study are expected to be a new
129 system that is more effective in treating rosacea.

130

131 2. MATERIAL AND METHODS

132 2.1. Materials

133 Metronidazole (MNZ), Carbomer 940, triethanolamine (TEA), glycerin, and DMDM
134 Hydantoin were obtained from Sigma-Aldrich Pte Ltd. (Singapore). Geleol®/glycerol
135 monostearate was kindly provided by Gattefosse Pvt. Ltd., France. Other materials were
136 analytical grade.

137 2.2. Preparation of metronidazole (MNZ) - loaded solid lipid microparticles (SLM)

138 MNZ-loaded SLM was prepared using the double emulsification method with glyceryl
139 monostearate (GMS) as a matrix-forming lipid. The SLM formulation in this study used five
140 different concentration ratios of GMS: MNZ, namely 1:2, 2:1, 3:1, 4:1, and 5:1 %w/w,
141 respectively marked as SLM 1, SLM 2, SLM 3, SLM 4, and SLM 5. Initially, SLM was
142 prepared by dissolving MNZ in water. Then, the solution was emulsified in chloroform
143 containing lipids and an emulsifier (to form a water-in-oil (W/O) emulsion) in a probe sonicator
144 adjusted at 80% amplitude with 10 s pulse on and 5 s pulse off for 1 minute. The previously
145 prepared w/o emulsion was emulsified again in water containing 1% poly(vinyl alcohol) (PVA)
146 to form water-in-oil-in-water (W/O/W) in the sonicator probe. After that, the organic solvent
147 in the double emulsion was evaporated by stirring the double emulsion at room temperature
148 for 6 hours to form SLM. To produce concentrated SLMs and separate free MNZ from the
149 SLMs, the formulation was centrifuged at 5,000 rpm for 30 min using an Amicon® Ultra
150 Centrifugal Device (Millipore Inc, molecular weight cut-off (MWCO) of 12 kDa). The
151 obtained microparticles were resuspended with 2.5% w/v PVP before the lyophilization
152 process. After that, to produce dry powder particles, the mixture was transferred to a freeze-
153 dryer for 26 hours (Permana et al., 2019).

154 2.3 Characterization of MNZ-loaded SLM

155 2.3.1 Particle size and polydispersity index (PDI)

156 The determination of the size and particle size distribution of the MNZ-loaded SLM
157 formula was analyzed by light scattering technique using Mastersizer 2000® equipment

158 (Malvern Instruments Ltd., UK) (Ghaderi et al., 2014; Rahimpour et al., 2016). This
159 measurement was made in three replications.

160 2.3.2 *Entrapment efficiency (EE) and drug loading (DL)*

161 Entrapment efficiency and drug loading of MNZ-loaded SLM were determined using
162 the method according to the method described previously (Wolska and Brach, 2022). The
163 amount of MNZ encapsulated in SLM was determined by dissolving SLM in methanol. The
164 MNZ-loaded SLM suspension that had been prepared was then centrifuged, and the
165 supernatant obtained was analyzed using a UV-Vis spectrophotometer at 320 nm. The
166 percentage of EE and DL can be calculated using the equation below.

$$167 \quad EE (\%) = \frac{W_{\text{total drug}} - W_{\text{free drug}}}{W_{\text{total drug}}} \times 100 \quad (1)$$

$$168 \quad DL (\%) = \frac{W_{\text{total drug}} - W_{\text{free drug}}}{W_{\text{lipid}}} \times 100 \quad (2)$$

169 Where, $W_{\text{total drug}}$ is the amount of drug added in the formulation, $W_{\text{free drug}}$ is the amount of free
170 drug in the aqueous phase or which is not encapsulated after separation from SLM, and W_{lipid}
171 is the weight of the lipid phase.

172 2.3.3 *Characterization of MNZ-loaded SLM*

173 The surface morphology of the optimized SLM formulation was observed using
174 scanning electron microscopy (SEM) (JEM-1400Plus; JEOL, Tokyo, Japan). Other analyses
175 were also carried out on MNZ and SLM (a mixture of pure drug and lipid), such as differential
176 scanning calorimetry (DSC) and x-ray diffraction (XRD) measurements of MNZ and SLM
177 formula using differential scanning calorimetry (DSC 2920, TA Instruments, Surrey, UK) and
178 X-ray diffractometer (Rigaku Corporation, Kent, UK), respectively. Then, to see the possibility
179 of chemical interactions between the drug and the compounds used in the formulation, an
180 analysis was carried out using a Fourier transform infrared spectrometer (FTIR) (Shimadzu®
181 FTIR-8400) (Permana et al., 2020a).

182 2.3.4 *In vitro drug release study*

183 The release of MNZ from SLM was carried out using the dialysis method with
184 Spectra/Por® 2, MWCO 12,000 to 14,000 (Spectrum Medical Industries, CA, USA) as dialysis
185 membranes. The release profile of MNZ as a free drug and MNZ-loaded SLM was determined
186 by inserting a dialysis membrane containing the formula into 100 mL of phosphate buffer saline
187 (PBS) medium pH 7.4 as a release medium in an orbital shaker at a speed of 10 rpm and a
188 temperature of 37°C. At certain time intervals, a 1 mL aliquot of the sample was taken and
189 replaced with a fresh release medium. The amount of MNZ drug released from SLM was then

190 analyzed using a UV-vis spectrophotometer with a wavelength of 320 nm. The in vitro drug
191 release kinetics can be calculated using the equation in section 2.4 (Permana et al., 2019).

192 2.4 Mathematical modeling of drug release kinetic

193 The dissolution data obtained can be analyzed to determine drug release kinetics both in
194 vitro and ex vivo. There are five mathematical models that can be applied to the release process
195 to determine the most suitable release kinetics, such as the zero-order release equation (ZO),
196 the first order equation (FO), the Higuchi square root equation (H), the Korsmeyer-Peppas
197 equation (KP), and the Hixson-Crowell (HC) square root model (Sulistiawati et al., 2021).

$$198 \quad ZO: C_t = C_0 + K_0 t \quad (3)$$

$$199 \quad FO: \ln C_t = \ln C_0 + K_1 t \quad (4)$$

$$200 \quad H: C_t = K_H \sqrt{t} \quad (5)$$

$$201 \quad KP: C_t = K_{KP} t^n \quad (6)$$

$$202 \quad HC: C_t^{1/3} = C_0^{1/3} K_{HC} t \quad (7)$$

203 C_t represents the concentration of MNZ released at time t , C_0 represents the initial
204 concentration of MNZ in the dissolution medium ($t = 0$) and K_0 , K_1 , K_H , K_{KP} , dan K_{HC} represent
205 the release constants zero-order, first-order, Higuchi, Korsmeyer-Peppas, and Hixson-Crowell
206 (Elmas et al., 2020; Sulistiawati et al., 2021). All of the above parameter calculations were
207 processed using DD-solver software (China Pharmaceutical University, Nanjing, China)
208 (Zhang et al., 2010).

209 2.5 Preparation of SLM-Loaded Gel

210 The optimal SLM formulations were then incorporated into gel preparation (details of
211 the composition of the SLM-loaded gel formula can be seen in Table 1). Briefly, the gel was
212 made by dispersing carbomer into distilled water and left to hydrate for one day. After
213 hydration, the carbomer polymer was neutralized with triethanolamine and homogenized using
214 the Ultra-Truax IKA® T18 basic homogenizer (IKA, Campinas, Brazil) at 15,000 rpm for 15
215 minutes. Glycerin, DMDM hydantoin, and MNZ-Loaded SLM were then added slowly to the
216 mixture and homogenized again until an evenly distributed SLM-Loaded Gel was obtained.

217

218

219

220

221

222

223

Table 1. Composition of SLM-Loaded Gel

Composition	%Composition (w/w)			
	F1	F2	F3	F4
MNZ-loaded SLM (equivalent 1% MNZ)	1,28	1,28	1,28	1,28
Carbomer 940	0,75	1	1,25	1,5
Triethanolamine	1	1,5	1,75	2
Glycerin	15	15	15	15
DMDM Hydantoin	0,1	0,1	0,1	0,1
Distilled water	ad 100	ad 100	ad 100	ad 100

224

225 *2.6 Characterization of SLM-Loaded Gel*226 *2.5.1. pH, viscosity and rheological examination*

227 The pH of the SLM-loaded gel formula was determined using a digital pH meter (Horiba
228 Scientific, Kyoto, Japan) with three replications at 25°C. Prior to measurement, the pH meter
229 was calibrated with the help of a pH 7 buffer solution. Then the electrode was immersed in the
230 gel formula (Dudhipala & Gorre, 2020; Thomas et al., 2019). The viscosity and rheology of
231 the SLM-Loaded Gel formula were determined using a Brookfield viscometer (model RV) at
232 25°C, each measured with three replications using spindle 7. In the determination of viscosity,
233 it was measured at a speed of 50 rpm. Meanwhile, for the determination of rheology, the gel
234 was rotated in stages at 5, 10, 20, 50, and 100 rpm (Himawan et al., 2022; Permana et al.,
235 2021b).

236 *2.5.2. Spreadability test*

237 The SLM-loaded gel (1 g) was placed between two glass plates (20 x 20 cm). The
238 standard weight of the top glass plate was 125 g. The sample was measured after 1 minute, and
239 then 100 g was added to the load until the final weight of the top plate was 525 g. The diameter
240 of the sample was measured with each additional load, and the procedure was repeated three
241 times. Next, the dispersion curve is made by plotting the load against the diameter formed
242 (Aliyah et al., 2021; Permana et al., 2020b).

243 *2.5.3. Extrudability test*

244 The gel extrudability test was carried out by filling 20 g of gel into a collapsible
245 aluminium tube and sealed with crimping at both ends. The tube containing the preparation
246 was then weighed and placed between two clamped glass slides. Next, on a glass slide, a load
247 of 500 g was given, and the tube cap was removed (Dudhipala and Gorre, 2020; Kaur and

248 Ajitha, 2019). This test was carried out in three replications, and extrudability was calculated
249 using the equation:

$$250 \text{ Extrudability (g/cm}^2\text{)} = \text{Weight applied to extrude gel/ Area} \quad (8)$$

251 2.5.4. *In vitro skin occlusivity evaluation*

252 The occlusivity of the SLM-loaded gel was evaluated in vitro by weighing each gel
253 formula (250 mg) and applying it to the surface of the Whatman No. 42 filter paper, with a
254 pore size of 2.5 μm (n = 3). The filter paper was used to cover a 100 mL beaker that had been
255 filled with 50 mL distilled water. As a test control, filter paper without gel formula was used.
256 Furthermore, the beakers were stored in an incubator at $32 \pm 0.5^\circ\text{C}$, and the weight of the system
257 was recorded at specified time intervals (0, 6, 24, and 48 hours) (Malik and Kaur, 2018;
258 Permana et al., 2020b). Occlusivity (F_0) is calculated using the following equation:

$$259 F_0 = \frac{W_0 - W_1}{W_0} \times 100 \quad (9)$$

260 Where, W_0 is the water loss from the control and W_1 is the water loss from the gel formula.

261 2.5.5. *Gel strength determination*

262 The strength of the SLM-loaded gel was determined according to (Algahtani et al., 2020).
263 The 60 g gel sample was put into a 100 ml measuring cup (d = 1.5 inches). Then, the mounted
264 disk (d = 3 cm; thickness = 3 mm) weighing 30 g was deposited on the gel surface. The strength
265 of this SLM-loaded gel was measured as the time (seconds) required for the disc to sink 5 cm
266 from the surface into the gel.

267 2.5.6. *Ex vivo skin permeation and retention studies*

268 **The** ex vivo skin permeation test used the Franz diffusion cell method with a diffusion
269 area of 4.9 cm^2 . This study used skin from the abdomen of rats as a diffusion membrane which
270 was carefully taken and then washed with PBS solution pH 7.4. Washed mouse skin was placed
271 between the donor compartment and the Franz diffusion cell receptor. The receptor
272 compartment with a capacity of 28 ml was filled with PBS solution pH 7.4 and stirred using a
273 magnetic stirrer at a speed of 100 rpm. The temperature was maintained at $37 \pm 1^\circ\text{C}$. A 1 g gel
274 sample (containing 10 mg MNZ) was introduced into the donor compartment. At certain time
275 intervals (0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 7, 8, and 24 h), 1.5 ml of receptor medium was sampled
276 and replaced with the fresh medium of the same volume in the receptor medium. The MNZ
277 concentration was then analyzed using a UV-vis spectrophotometer (Dynamica, HALO XB-
278 10) with a validated wavelength of 320 nm (Neupane et al., 2020; Permana et al., 2020b). The
279 cumulative drug released was calculated using the equation in section 2.4. The permeation rate

280 of the preparation can also be calculated using Fick's first law equation, equation 10 (Berthet
281 et al., 2020; de Araújo et al., 2021).

$$282 \quad J (\mu\text{g}/\text{cm}^2/\text{h}) = \frac{dM}{S \cdot dt} \quad (10)$$

283 Where, M is the amount of drug absorbed, S is the area of diffusion, and t is the time.

284 At the end of the permeation study, after 24 hours, the retention test was continued. The
285 skin of the used mice was carefully removed from the Franz diffusion cells and washed three
286 times with fresh receptor medium to remove excess formula. The skin was cut into small pieces,
287 and the MNZ retained in the skin was extracted with 20 mL of methanol, then homogenized at
288 1000 rpm for 15 minutes. Samples were centrifuged for 30 minutes at a speed of 5000 rpm.
289 The supernatant obtained was collected and analyzed by UV-vis spectrophotometry (Badie and
290 Abbas, 2018).

291 2.7 *In vitro* hemolysis test of MNZ-loaded SLM and SLM-Loaded Gel

292 *In vitro* hemolysis toxicity screening of MNZ-loaded SLM and SLM-loaded gel was
293 carried out following the previously described spectrophotometric method (Enggi et al., 2021;
294 Khurana et al., 2013). Briefly, red blood cells (RBC) obtained from Wistar rats were
295 centrifuged at 2000 rpm for 20 min to separate RBC from plasma. The RBCs were then washed
296 three times with PBS (pH 7.4) and resuspended with PBS to obtain a 10% (v/v) RBC stock
297 dispersion. A total of 0.1 ml of the tested sample was then added to 0.9 ml of RBC and
298 incubated for 1 hour at $37 \pm 0.5^\circ\text{C}$. After incubation, the samples were centrifuged at 1500 rpm
299 for 10 min. The preparation of positive and negative controls was carried out by adding 0.1 mL
300 of RBC dispersion with 0.9 mL of Solution X-100 (5% v/v) and 0.9 mL of PBS (pH 7.4),
301 respectively. To determine the content of oxyhemoglobin released, the supernatant from the
302 test sample, positive control, and negative control was analyzed using a UV-Vis
303 spectrophotometer at 546 nm (Dynamica, HALO XB-10). The percentage of hemolysis was
304 calculated using the following equation:

$$305 \quad \text{Hemolysis (\%)} = \frac{(\text{OD test sample}) - (\text{OD negative control})}{(\text{OD positive control}) - (\text{OD negative control})} \times 100 \quad (11)$$

306 2.8 *In vitro* antioxidant activity

307 The antioxidant capacities of MNZ, MNZ-loaded SLM and SLM-loaded gel were
308 assessed using 2,2-diphenyl-1-picrylhydrozyl (DPPH) radical and lipid peroxidation method,
309 as described previously (Permana et al., 2020b). In DPPH method, the tested compounds were
310 dissolved in methanol (2.5 mL) in different concentrations. These solutions were mixed with
311 DPPH solution (2.5 mL) and incubated in the dark for 20 min. The absorbances were

312 determined at 520 nm using spectrophotometric. The concentration of the tested compound,
313 which could inhibit 50% of DPPH, expressed as IC₅₀ was finally determined. In lipid
314 peroxidation method, the emulsion composed of 0.25 g of linoleic acid, 0.25 g of Tween 80
315 and 20 mL of 20 mM phosphate buffer (pH 7) was mixed with the tested compounds with the
316 same ratio. The mixture was incubated for 6 h at 37 °C. Following this, 0.1 mL of the mixture
317 was mixed with 5 mL of ethanol (75% v/v), 0.1 mL of 20 mM of ferrous chloride in 100 mM
318 HCl and 0.2 mL of 30% w/v ammonium thiocyanate, and was incubated for 5 min at 25 °C.
319 The absorbances were determined at 500 nm using spectrophotometric, and the IC₅₀ values
320 were determined.

321 2.9 Statistical analysis

322 Data are presented as mean ± standard deviation (SD). All results obtained were
323 calculated using Microsoft Excel® 2016 (Microsoft Corporation, Redmond, USA). Statistical
324 analysis was performed using IBM® SPSS® Statistics 21.0 (IBM, Armonk, New York, USA).
325 The data obtained were processed in graphs and diagrams using GraphPad Prism® version 5
326 (GraphPad Software, San Diego, California, USA). The probability level of $p < 0.05$ was
327 considered significant.

328

329 3. RESULTS AND DISCUSSION

330 3.1. Preparation and Optimization of MNZ - loaded SLM


331 In this study, MNZ-loaded SLM was prepared using the double emulsification method.
332 MNZ is a hydrophilic drug (Shinde et al., 2019). The double emulsification method has become
333 one of the ideal methods in the preparation of SLM containing hydrophilic drugs. This is
334 evidenced by several previous studies that have been described by Mirchandani et al. (2021).
335 Multiple emulsion systems (water-in-oil-in-water, w/o/w) can provide better entrapment of
336 hydrophilic drugs (Akki et al., 2022). In addition, SLM prepared by this method can avoid the
337 partition of hydrophilic drugs that are released from the oil phase to the outer phase (water)
338 during the emulsification process. In order to support this, the drug is packaged with a
339 stabilizer. In this study, 1% PVA was used as a stabilizer (Dolatabadi et al., 2015; Shi et al.,
340 2011). Then, in a solid lipid microparticle system, in order for the drug to be well encapsulated,
341 the drug must be soluble in the lipid matrix. Based on research by Shinde et al. (2019), glyceryl
342 monostearate (GMS) is a solid lipid that can provide high dissolution of MNZ because GMS
343 has slightly hydrophilic properties with one ester group and two hydroxyl groups, so it can
344 form hydrogen bonds between the groups of GMS and MNZ.

345 The ratio of lipids to drugs in the preparation of SLM was the main independent factor that
346 could influence the formation of an optimal microstructured solid lipid system (Nabi-Meibodi
347 et al., 2013). Therefore, this study began by evaluating the SLM system based on various
348 characteristic parameters, such as particle size, polydispersity index (PDI), entrapment
349 efficiency (EE), and drug loading (DL). The results of the evaluation can be seen in Table 2.
350 The determination of the particle size of the SLM formula showed that the higher the lipid
351 concentration, the greater the particle size (Fig. 1 (A)). Meanwhile, for PDI, all SLM formulas
352 are in the range of 0.102 – 0.119. The good particle size for topical application is 1 – 3 μm , so
353 the results obtained indicated that SLM 5 did not meet the standardization of optimal SLM for
354 topical drug delivery systems (Rahimpour et al., 2016). In addition, the statistical analysis
355 results also showed significantly different values ($p < 0.05$) between SLM 4 and SLM 5. The
356 smaller the size of a particle, the more the surface area of the particle increases, which causes
357 its solubility to increase. Therefore, the particles are more easily absorbed into the body
358 (Rabima and Sari, 2019). Then, for PDI, it showed that all formulas met the PDI parameter
359 standard, which is < 0.3 , with excellent homogeneity (Algul et al., 2018; Kazemi et al., 2014).
360 This also indicated that the SLM system was more stable because only a few particles
361 underwent aggregation (Rabima and Sari, 2019).

362 The success of the preparation of the SLM system is very dependent on how much the
363 active substance is absorbed into the system. Fig. 1 (B) shows the increased efficiency of drug
364 entrapment into the SLM system and the increased lipid concentration. Statistical analysis
365 showed that the SLM 4 formulation, with an EE value of $88.43 \pm 3.12 \%$, was a formula with
366 a good EE value because it has a significantly different value ($p < 0.05$) from the formulation
367 SLM 1, SLM 2, SLM 3, and not significantly different ($p > 0.05$) from the SLM 5 formula. The
368 lipid concentration used affected the entrapment efficiency produced because the lipid chains
369 play a role in the formation of imperfect crystals so that they can provide a larger space in the
370 crystal that can accommodate more drugs (Soute and Müller, 2007). The higher the EE value
371 produced, the greater the amount of drug that is absorbed into the system (Lv et al., 2018). In
372 addition to the EE value, drug loading (DL) is also a factor in the success of SLM preparation.
373 The results of the DL evaluation can be seen in Table 2, Fig. 1 (B), which showed results that
374 were inversely proportional to the EE value. The EE and DL capacities are closely related to
375 the particle size and the particle formation process of the SLM system. In addition, solid lipid
376 particles also have limited drug loading capacity for hydrophilic drugs (Mu and Holm, 2018).

377 After conducting several SLM characterization tests above, it was concluded that SLM 4
378 was the optimal MNZ-loaded SLM formulation. Accordingly, it was continued for further

379 evaluation and preparation of SLM-loaded gel with particle sizes and PDI that meet SLM
 380 standards as a drug in overcoming rosacea with a topical drug delivery system and have higher
 381 EE and DL values, with values that are not significantly different ($p>0.05$) from SLM 5.
 382 Although the EE and DL values of SLM 5 were larger, they produced a particle size larger than
 383 3 μm .



384
 385 **Figure 1.** (A) Particle size, polydispersity index (PDI), (B) entrapment efficiency (EE), and drug loading (DL) of
 386 MNZ-loaded SLM (means \pm SD, $n = 3$).

387 **Table 2.** Results of particle size, PDI, EE, and DL of MNZ-loaded SLM formulation (means \pm SD, $n = 3$, $* = p <$
 388 **0.05**)

Formula	GMS : MNZ	Particle Size (μm)	PDI	EE (%)	DL (%)
SLM 1	1 : 2	0,98 \pm 0.05	0,102 \pm 0.018	49.19 \pm 2.12	32.09 \pm 2.09
SLM 2	2 : 1	1.26 \pm 0.11	0,112 \pm 0.013	58.83 \pm 3.21	28.12 \pm 1.98
SLM 3	3 : 1	1.65 \pm 0.14	0,107 \pm 0.011	69.94 \pm 4.09	29.19 \pm 1.77
SLM 4	4 : 1	2.69 \pm 0.29	0,119 \pm 0.014	88.43 \pm 3.12	26.34 \pm 2.19
SLM 5	5 : 1	5.84 \pm 0.43*	0,106 \pm 0.009	90.31 \pm 4.18	24.09 \pm 2.87

389
 390 **3.2 Characterizations of MNZ-loaded SLM**

391 The optimal morphology of the MNZ-loaded SLM (SLM 4) was observed using SEM
 392 analysis. The results of the analysis showed that the microparticles formed had a spherical and
 393 smooth shape (Fig 2 (D)). This form is a type of good solid lipid microparticle morphology
 394 (Oriani et al., 2016). The results of these observations confirm the optimal particle size and
 395 size distribution of SLM, which have been obtained previously using the Mastersizer 2000[®],
 396 with values of 2.69 \pm 0.29 μm and 0.119 \pm 0.014 for particle size and size distribution,
 397 respectively. The spherical morphology of microparticles has the advantage of being able to
 398 reduce the occurrence of aggregation, which can affect the surface area of the particles as well
 399 as the absorption of particles (Bertoni et al., 2020; Oriani et al., 2016). Then, the interaction
 400 between the drug and excipients was observed using FTIR analysis. Fig. 2 (A) shows the FTIR

401 spectrum of MNZ as a free drug and optimal MNZ-loaded SLM. The spectrum confirms that
402 there was no interaction between the active substance and additives in the SLM system that
403 can cause drug degradation, where the MNZ-loaded SLM spectrum still exhibited the same
404 functional groups found in free MNZ. Based on observations, the infrared spectrum of MNZ-
405 loaded SLM was as follows: stretching at 3215 cm^{-1} (for the OH group), 3102 cm^{-1} (C=CH),
406 1529 cm^{-1} (NO₂/N-O), 1189 cm^{-1} (stretching vibration of a tertiary amine group), 1075 cm^{-1}
407 (C-OH/C-O), and 865 cm^{-1} (C-NO₂).

408 The solid-state study of the produced SLM was further analyzed using DSC and XRD
409 (spectra can be seen in Fig. 2 (B) and (C), respectively). DSC analysis was carried out to
410 evaluate the thermal profile, crystallization, and possible interactions between drugs and
411 excipients (Agubata et al., 2014; Rahimpour et al., 2016). The DSC profile of MNZ shows an
412 endothermic peak with a melting point at 160°C , while the profile of MNZ-loaded SLM shows
413 no peak, which means that there was a change in the solid form of MNZ from a crystalline to
414 an amorphous form after encapsulation. The amorphous form does not have a melting
415 endotherm, so the DSC profile of MNZ-loaded SLM does not show any peaks (Thakkar et al.,
416 2021). The results of the analysis also indicated that MNZ was perfectly encapsulated in the
417 SLM system. To further confirm the solid form of MNZ-loaded SLM, XRD analysis was
418 performed. Based on the analysis results, XRD spectra also show that in pure MNZ, there was
419 a peak in the 13° to 27° area. The appearance of these peaks indicates that MNZ is in the
420 crystalline phase. Still, after being encapsulated in the SLM system, MNZ underwent a
421 transformation to an amorphous phase, which was characterized by a significant decrease in
422 the diffraction peaks on the diffractogram.




Figure 2. (A) FTIR spectra, (B) DSC thermogram, and (C) X-ray diffractogram of pure MNZ and optimal MNZ-loaded SLM. (D) SEM image of MNZ-loaded SLM optimal.

423


424

425

426

427 3.3 *In vitro* drug release study

428 *In vitro* drug release study was conducted to compare the release profile of pure MNZ
 429 (before encapsulation) with MNZ-loaded SLM (MNZ after encapsulation). The drug release
 430 profile obtained can be seen in Fig. 3. The figure shows that pure MNZ has a faster release rate
 431 than MNZ after encapsulation, i.e. after 2 hours, the drug has been dissolved in pure drug by
 432 $99.18 \pm 7.98\%$. This was also because pure MNZ has high hydrophilicity, so it can be released
 433 in just 2 hours (Shinde et al., 2019). Meanwhile, the release rate of MNZ-loaded SLM showed
 434 a slower and sustained release, which might be due to the slower diffusion of MNZ
 435 encapsulated in the SLM system from the lipid core (Permana et al., 2019). El-Housiny et al.
 436 (2018) revealed that the concentration of lipids used in the SLM formulation could affect drug
 437 diffusion. As the concentration of lipids increases, the thickness of the lipid matrix in the SLM
 438 system also increases, which means an increase in the length of diffusion, which results in a
 439 decrease in the rate of drug release.



440

441

Figure 3. In vitro release profiles of optimal MNZ-loaded SLM in comparison with the pure MNZ

442

443

444

445

446

447

448

449

450

451

452

3.4 Preparation of SLM-Loaded Gel

453

454

455

456

457

458

459

460

461

462

463

464

465

The optimized MNZ-loaded SLM was then incorporated into the gel base. The SLM-loaded gel formulation was made with the aim of increasing the bioavailability of MNZ as well as controlling the release of MNZ on the skin after application. To obtain the optimal SLM-loaded gel formula, this formulation used a variation of the concentration of carbomer: triethanolamine (TEA) namely 0.75%:1%, 1%:1.5%, 1.25%:1.75%, and 1.5%:2% for F1, F2, F3, and F4, respectively. The choice of polymer used is one of the most important factors in the formulation. Carbomer polymers are used as gelling agents. In this study, carbomer was chosen because it has ideal characteristics, such as ease of preparation, and can form gels at low concentrations. This polymer has been widely used in topical formulations (Khurana et al., 2020). Then, other additives used are TEA as an alkalizing agent, which is related to the formation of pH and gel matrix from carbomer through the formation of the polymer chain (Safitri et al., 2021), glycerin as a humectant, DMDM hydantoin as a preservative, and distilled water as a carrier.

466 3.5 pH, viscosity and rheological examination

467 The results of determining the pH and viscosity of the SLM-loaded gel can be seen in
468 Table 3. Based on the results of measurements of pH and viscosity of the formulation of the
469 SLM-loaded gel, it shows that the concentration of carbomer has a significant effect ($p < 0.05$)
470 on the pH and viscosity of the gel preparation produced. In each formulation, the pH conditions
471 of the preparations made must be adjusted in such a way according to the conditions at the
472 targeted location so as not to cause irritation and disrupt the function of cell membranes in the
473 body (Luki et al., 2021). The ideal pH value for the skin is in the range of 4 – 7, so the pH of
474 the SLM-loaded gel formulations shows that all formulas have a safe pH that can be accepted
475 by the skin (Lambers et al., 2006). Gel viscosity generally describes the consistency of the gel.
476 It is one of the important parameters in gel formulation because it can affect drug release and
477 extrudability of the gel preparation produced (Ontong et al., 2020). According to Rowe et al.
478 (2009), the viscosity of the polymer Carbopol 940 (0.5% w/v) has a viscosity of around 40,000
479 – 60,000 mPa.s. Thus, the results indicated a decrease in the viscosity of the gelling agent used,
480 which may be due to adding active ingredients and other additives in the formulation. However,
481 the viscosity produced from all SLM-loaded gel formulas still showed good viscosity for
482 topical drug delivery (Ankita et al., 2020; Singh et al., 2013).

483 Fig. 4 shows the results of the rheological measurements of the SLM-loaded gel formula.
484 It can be seen that the rheogram for formulations F1, F2, and F3 has a pseudoplastic flow type,
485 where there is a decrease in viscosity with an increasing shear rate (rate of share). The curved
486 rheogram in pseudoplastic flow was caused by the interaction between the applied force and
487 the polymer molecules used. As the applied force increases, the polymer molecules, which
488 were normally irregular, would begin to form long chains following the direction of flow. This
489 change in polymer composition would reduce the resistance of the material used and result in
490 a greater change in the shape of the flow at shear stress (Abate and Abel, 2006; Güllü et al.,
491 2020). Meanwhile, the F4 formulation showed a rheogram with a dilatant flow type, where
492 there is a decrease in viscosity by increasing the shear rate (Güllü et al., 2020). Viscosity is
493 influenced by the amount of solute concentration in it. F4 had the highest carbomer
494 concentration, 1.5%, so it had a higher viscosity, which could cause a dilatant-type flow.




Figure 4. Rheological examination of SLM-loaded gel

495

496

497 3.6 Spreadability test

498 One aspect of the efficacy of SLM-loaded gel therapy depends on its spread when applied
 499 (Ontong et al., 2020). Gels with good spreadability can optimize drug absorption into the skin
 500 faster because in the topical application, the high spreadability causes the contact between the
 501 drug and the skin to be wider (Safitri et al., 2021). The results of the evaluation of the
 502 spreadability of SLM-loaded gel can be seen in Table 3, which showed **desired** spreadability.
 503 **It was found that the** concentration of carbomer used can affect the spreadability of the gel with
 504 significantly different results ($p < 0.05$) between the formulas. The higher the concentration of
 505 carbomer, the lower the spreadability produced. This was related to the viscosity obtained; the
 506 viscosity is inversely proportional to the spreadability (Aodah et al., 2021). The same results
 507 were also obtained in another study using carbomer 940 as a gelling agent with concentrations
 508 ranging from 0.5 to 2%, which showed increasing viscosity and lower spreadability, along with
 509 the increasing concentration of carbomer used (Alvionida et al., 2021; Rahmawati and
 510 Setiawan, 2019).

511

512 3.7 Extrudability test

513 The extrudability test of SLM-loaded gel was carried out to measure how much effort was
 514 needed to remove the gel formula from the tube after it was packaged, so that it could facilitate
 515 and provide comfort to the patient in its application (Dudhipala and Gorre, 2020; Rajan and
 516 Vasudevan, 2012). The test results of the extrudability of the SLM-loaded gel formula can be
 517 seen in Table 3. The results showed that the higher the concentration of carbomer used, the
 518 lower the extrudability value. It was found that F4 had the lowest extrudability value compared
 519 to other formulas, namely $1.05 \pm 0.17 \text{ g/cm}^2$, which was significantly different ($p < 0.05$) from

520 other formulations after statistical analysis. This was because carbomer 940 was used as a
 521 gelling agent in this study. Thus, the higher the concentration of carbomer used, the lower the
 522 extrudability value produced. Carbomers have different characteristics based on their
 523 molecular weight. Based on Ojha et al. (2021), carbomer 940 is a polymer with high viscosity
 524 characteristics compared to carbomers with other molecular weights, such as carbomers 910
 525 and 941. Thus, high viscosity can increase its consistency in the formulation and provide low
 526 extrudability values when used in higher concentrations.

527

528 3.8 Gel strength determination

529 Gel strength in the development of a formulation has become one of the critical parameters
 530 that must be considered, especially in its topical application. Before leaching from the target
 531 site, a strong gel would support a much greater pressure than a weak gel, thereby preventing
 532 rapid drainage of the formulation (Morsi et al., 2017; Priyanka et al., 2019). The results of
 533 determining the gel strength of the SLM-loaded gel formulation can be seen in Table 3. Based
 534 on the results obtained, it showed that the higher concentration of carbomer used, the stronger
 535 the gel strength produced. However, these results showed that the values were not significantly
 536 different ($p > 0.05$) between one formula and another after statistical analysis was performed.
 537 The value of a good gel strength was in the range of 25 to 50 seconds. It was previously reported
 538 that when the values were below 25 seconds, the gel produced was too weak and could not
 539 maintain its integrity. Therefore, it was easily eroded, whereas if the value was above 50
 540 seconds, the resulting gel was too stiff and could cause discomfort on the skin surface (Mahajan
 541 et al., 2012; Morsi et al., 2017). Accordingly, it can be said that the gel strength between one
 542 SLM-loaded gel formula and the other had similarities and was in a good gel strength range.

543

544


545 **Table 3.** Results of pH, viscosity, spreadability, extrudability, and gel strength determination of SLM-loaded gel
 546 formulations (means \pm SD, n = 3, * = $p < 0.05$)

Formula	pH	Viscosity (mPa.s)	Spreadability (mm)	Extrudability (g/cm ²)	Gel strength (s)
F1	6.74 \pm 0.01	24900 \pm 1053.57	4.10 \pm 0.75	1.54 \pm 0.19	38.10 \pm 4.14
F2	6.85 \pm 0.02	31866.67 \pm 65.64*	3.78 \pm 0.67	1.49 \pm 0.21	40.32 \pm 4.31
F3	6.89 \pm 0.02	37233.33 \pm 1514.38*	3.55 \pm 0.63	1.41 \pm 0.18	41.98 \pm 4.19
F4	6.95 \pm 0.02	46766.67 \pm 2722.74*	3.31 \pm 0.63	1.05 \pm 0.17	42.43 \pm 4.82

547

548 3.9 In vitro skin occlusivity evaluation

549 The in vitro skin occlusivity test on the produced SLM gel formulation aimed to increase
550 the ability while maintaining skin hydration characteristics topically (Kenechukwu et al.,
551 2017). The test results can be seen in Fig. 5, which indicated that the incorporation of SLM
552 into the gel in all formulations has a high occlusive value. This was related to the dense nature
553 of the lipid components used in the formulation by clogging the micropores of the filter, thereby
554 preventing water shortages to a greater extent (Kakkar et al., 2018; Mandawgade and Patravale,
555 2008). Several other studies have also reported comparisons of **occlusive skin** values obtained
556 between conventional gel formulas with active substances without encapsulation of solid lipids
557 and gels with active substances that have been encapsulated in solid lipids with the same
558 formulation using a carbomer base, showing that ordinary gels with active ingredients without
559 encapsulated solid lipids have a lower occlusive value than gels with active substances that
560 have been encapsulated in solid lipids (Bagde et al., 2019; Kakkar et al., 2018). In addition, the
561 effect of the high occlusiveness of the gel formula used in this rosacea can help the drug
562 penetrate deeper into the skin layer with the gaps between the corneocytes and clog the pores
563 in the skin layer to reduce some of the side effects, such as itching, dryness, and scaling (Bagde
564 et al., 2019; Kenechukwu et al., 2017).
565



566 **Figure 5.** In vitro skin occlusivity of SLM-loaded gel (means \pm SD, n = 3)
567

568
569

570 3.10 Ex-vivo skin permeation and retention studies

571 To determine the effectiveness of the SLM-loaded gel formulation produced and the
572 previously optimized MNZ-loaded SLM in drug delivery, ex vivo permeation, and retention
573 tests were carried out as this study's final proof of concept. The release pattern of MNZ-loaded
574 SLM from the gel was evaluated using a Franz diffusion cell with mouse skin as a diffusion
575 membrane through which the gel would pass. In this study, a gel formulation containing 1%
576 pure MNZ that was not formulated into the SLM system was used as a control. Fig. 6 (A) and

577 (B) show the cumulative amount and rate of drug release (flux) from the SLM-loaded gel
578 formula through the skin of rats after 24 hours. The cumulative amount of MNZ and the
579 permeated drug release rate in formulations F1 to F4 decreased because the higher viscosity
580 values could affect the diffusion rate of the drug to permeate.

581 Based on the research of Yen et al. (2015), an in vitro drug release test showed that the
582 concentration of carbomer affects drug permeation due to the complexity of the gel network
583 that affects drug diffusion pathways to be absorbed through the membrane. However, the
584 results obtained after statistical analysis showed no significant difference ($p > 0.05$) between
585 formulations F1 and F4. Furthermore, when compared with formulas F1 to F4, the control
586 formula showed the highest cumulative amount of permeated drug with significantly different
587 results ($p < 0.05$). MNZ belongs to BCS class 1, which means it has high permeability and
588 solubility, allowing for higher drug release in the control formula (Zhang et al., 2019). Then
589 the gel formula with encapsulated MNZ showed a slower rate of drug release from formulations
590 F1 to F4. In addition to the effect of carbomer concentration, another thing that might affect
591 drug penetration was the diffusion distance due to the lipid content and high affinity of the drug
592 in the lipid matrix in the SLM system on the gel and the speed of drug partitioning from the
593 lipid phase to the receptor compartment (El-kamel et al., 2007; Rahimpour et al., 2016). Thus,
594 the drug encapsulated in the gel formulation exhibited a **slow-release** of the drug.

595 To better understand and correlate the MNZ permeation pattern of the SLM-loaded gel,
596 mathematical modeling kinetics was applied to the release profile of the obtained gel (Table
597 4). When the correlation coefficient (r^2) values of each kinetic model were compared, all gels
598 were found to exhibit a release pattern behavior following the Korsmeyer-Peppas kinetic
599 model. The obtained Korsmeyer-Peppas diffusion exponents (n) were 0.816, 0.452, 0.707,
600 0.903, and 0.656 for F1, F2, F3, F4, and control, respectively. When the diffusion exponents
601 obtained were in the range of 0.45 and 0.89, the F1, F2, F3, and control formulations showed
602 a diffusion anomaly (non-Fickian) which means that the release of MNZ from the SLM-loaded
603 gel occurs through a combination of controlled diffusion and erosion processes. When the value
604 was ≥ 0.89 for the F4 formula, the formula followed the release of MNZ with a super case-II
605 transport mechanism, namely a mechanism controlled by swelling and relaxation of the
606 hydrophilic polymer (Bera et al., 2016; Das et al., 2013; Ignjatović et al., 2021).

607 One of the goals of the SLM system was to control the release of MNZ and increase its
608 retention time in the skin (Jaspart et al., 2007). Therefore, in this study, a retention test was
609 conducted to determine the ability of SLM-loaded gel to increase drug retention in the skin.
610 Fig. 6 (C) shows the amount of MNZ deposited after 24 hours, with formula F3 being the

611 formula with the most MNZ being deposited at 2.53 ± 0.05 mg. Statistical analysis showed a
612 significantly different value ($p < 0.05$) between the F3 formula and other formulas, as well as
613 the control. The higher the carbomer concentration, the greater the amount of MNZ deposited.
614 This was due to an increase in viscosity, which maintained SLM particles in the preparation
615 and slowed down the rate of diffusion of drug molecules to permeate the skin. However, if the
616 viscosity value was too large, it could significantly impact the diffusion rate of drug molecules,
617 resulting in a lower amount of MNZ deposited on F4. Meanwhile, the control formulation
618 containing MNZ, which was not formulated into the SLM system, also resulted in a small
619 amount of MNZ being deposited due to the small molecule of MNZ, making it easier to
620 permeate through the membrane. Based on research by Rahimpour et al. (2016), drugs
621 formulated in the SLM system that was delivered in gel preparations could increase drug
622 retention in the skin. Therefore, MNZ, which was encapsulated in the SLM system and
623 formulated in a gel preparation with a carbomer concentration of 1.25% (F3), was chosen as
624 the optimal formula with good drug release and retention in delivering the drug topically.


625

626 **Table 4.** Mathematical modelling of ex vivo release kinetics parameters

Formula	Zero-Order		First-Order		Higuchi		Hixson-Crowell		Korsmeyer-Peppas		
	k_0	R^2	k_1	R^2	k_H	R^2	k_{HC}	R^2	k_{KP}	n	R^2
F1	0.509	0.9340	0.005	0.9407	1.770	0.8354	0.002	0.9386	0.848	0.816	0.9642
F2	0.429	0.1900	0.005	0.2379	1.728	0.8501	0.001	0.2219	1.917	0.452	0.8582
F3	0.315	0.8576	0.003	0.8700	1.130	0.8842	0.001	0.8659	0.707	0.707	0.9600
F4	0.191	0.9574	0.002	0.9596	0.642	0.7768	0.001	0.9589	0.251	0.903	0.9649
Control	1.273	0.8049	0.015	0.8654	4.642	0.9162	0.005	0.8470	3.264	0.656	0.9642

627

628



629

630

631

Figure 6. Results of ex vivo skin permeation (A), permeation flux (B), and retention (C) test of SLM-loaded gel (means \pm SD, n = 3)

632

3.11 In vitro hemolysis test of MNZ-loaded SLM and SLM-Loaded Gel

633

634

635

636

637

638

639

640

641

642

643

644

645

646

To assess the safety and irritation potential of the resulting formula, a hemolytic activity test on red blood cells (RBC) was performed. Biomaterials that would be used for direct application to wounds of rosacea sufferers must be compatible with red blood cells so that hemostatic activity is not disturbed. Accordingly, it can adequately help the wound healing process (López- Iglesias et al., 2020). The results of the hemolytic activity test of free drug (pure MNZ), optimal MNZ-loaded SLM, and all SLM-loaded gel formulas showed a low percentage of hemolysis (Table 4). The hemolysis index was considered to be safe when the value was <5% (Enggi et al., 2021; Helal et al., 2016). Thus, from the results obtained, it can be concluded that the optimal SLM and the resulting gel were potentially safe and hemocompatible.

647 **Table 4.** Hemolysis percentage of free drug (pure MNZ), MNZ-loaded SLM, and SLM-loaded gel formulations
 648 (means \pm SD, n = 3)

Concentration ($\mu\text{g/mL}$)	Hemolysis (%)					
	Free drug	SLM	F1	F2	F3	F4
500	4.15 \pm 0.21	1.09 \pm 0.11	3.09 \pm 0.29	3.18 \pm 0.31	3.21 \pm 0.33	3.29 \pm 0.35
50	3.18 \pm 0.12	0.43 \pm 0.02	2.32 \pm 0.31	2.29 \pm 0.22	2.11 \pm 0.21	2.31 \pm 0.29
5	2.09 \pm 0.13	0.14 \pm 0.01	1.02 \pm 0.11	1.19 \pm 0.12	1.09 \pm 0.11	1.22 \pm 0.15

649 **3.12 In vitro antioxidant activity**

650 In the clinical manifestations of rosacea, free radicals have been found to play an important
 651 role in extrinsic and intrinsic aging. The reactive oxygen species produced by neutrophils can
 652 lead to damage to oxidative tissue (Miyachi, 2001). Accordingly, in this study, we evaluated
 653 the antioxidant activity of MNZ. In DPPH evaluations, the IC₅₀ values of free drug, SLM, F1,
 654 F2, F3 and F4 were found to be 103.88 \pm 9.34 $\mu\text{g/mL}$, 109.11 \pm 10.02 $\mu\text{g/mL}$, 102.65 \pm 8.08
 655 $\mu\text{g/mL}$, 112.43 \pm 11.31 $\mu\text{g/mL}$, 106.42 \pm 11.05 $\mu\text{g/mL}$ and 107.17 \pm 9.87 $\mu\text{g/mL}$, respectively.
 656 Furthermore, in the lipid peroxidation method, the IC₅₀ values were 121.03 \pm 11.31 $\mu\text{g/mL}$ for
 657 free drug, 126.03 \pm 11.98 $\mu\text{g/mL}$ for SLM, 131.45 \pm 12.01 $\mu\text{g/mL}$ for F1, 126.98 \pm 12.01 $\mu\text{g/mL}$
 658 for F2, 131.22 \pm 12.15 $\mu\text{g/mL}$ for F3 and 127.87 \pm 11.81 $\mu\text{g/mL}$ for F4. In both methods, there
 659 were no significant differences ($p > 0.05$) in the IC₅₀ values, indicating that the formulation of
 660 MNZ into SLM and hydrogel did not affect the antioxidant properties of MNZ.

661

662 **Conclusion**

663 This study focuses on developing a drug delivery system for treating rosacea with the
 664 hydrophilic drug MNZ. MNZ encapsulated in the SLM system has shown excellent quality
 665 characteristics with sustained in vitro drug release. The optimal SLM obtained was further
 666 developed in the form of a gel dosage form with a carbopol. The carbopol with 1.25% could
 667 provide optimal physical characteristics of the gel and show a better drug release profile, which
 668 was significantly different from the control formula and other formulations with the amount of
 669 permeated and retained MNZ of 0.64 \pm 0.07 mg and 2.53 \pm 0.05 mg, respectively. The
 670 developed MNZ-loaded SLM and SLM-loaded gel also showed that these formulations were
 671 hemocompatible, so they were safe to use in rosacea treatment. In the antioxidant evaluation,
 672 the formulation of MNZ into SLM and hydrogel did not affect the property of MNZ in
 673 inhibiting free radicals. However, further evaluation of the development of this system needs
 674 to be carried out, such as determining the kinetic profile of MNZ release from SLM-loaded gel
 675 in vivo using suitable experimental animals, stability testing, and irritation testing of SLM-

676 loaded gel to provide maximum results in the development of MNZ delivery systems for topical
677 rosacea therapy.

678

679 **Acknowledgements**

680 The authors wish to thank Gattefosse Pvt. Ltd., France for providing the lipids.

681

682

683 **Reference**

684 Abate, M., Abel, S.K., 2006. Remington: The Science and Practice of Pharmacy 21st Edition.
685 Lippincott Williams and Wilkins, Philadelphia.

686 Agubata, C., Chime, S., Kenekwku, F., Nzekwe, I., Onunkwo, G., 2014. Formulation and
687 characterization of hydrochlorothiazide solid lipid microparticles based on lipid matrices
688 of Irvingia fat. *Int. J. Pharm. Investig.* 4, 189–194. [https://doi.org/10.4103/2230-](https://doi.org/10.4103/2230-973x.143120)
689 [973x.143120](https://doi.org/10.4103/2230-973x.143120)

690 Akki, R., Bhattiprolu, S.S., Vinukonda, A., Kathirvel, S., 2022. An Overview on Liposheres.
691 *World J. Pharm. Res.* 11, 217–232. <https://doi.org/10.20959/wjpr20228-24470>

692 Algahtani, M.S., Ahmad, M.Z., Ahmad, J., 2020. Nanoemulsion loaded polymeric hydrogel
693 for topical delivery of curcumin in psoriasis. *J. Drug Deliv. Sci. Technol.* 59, 101847.
694 <https://doi.org/10.1016/j.jddst.2020.101847>

695 Algul, D., Duman, G., Ozdemir, S., Acar, E.T., Yener, G., 2018. Preformulation,
696 Characterization, and In Vitro Release Studies of Caffeine-Loaded Solid Lipid
697 Nanoparticles. *J. Cosmet. Sci.* 69, 165–173.

698 Aliyah, A., Oktaviana, W.W., Dwipayanti, K.S., Erdiana, A.P., Utami, R.N., Permana, A.D.,
699 2021. Enhanced skin localization of doxycycline using microparticles and hydrogel:
700 Effect of oleic acid as penetration enhancer. *Pharmaciana* 11, 239.
701 <https://doi.org/10.12928/pharmaciana.v11i2.21044>

702 Alvionida, F., Sulistyani, N., Sugihartini, N., 2021. Composition of carbopol 940 and HPMC
703 affects antibacterial activity of beluntas (*Pluchea indica* (L.)) leaves extract gel.
704 *Pharmaciana* 11, 427–438. <https://doi.org/10.12928/pharmaciana.v11i3.20017>

705 Ankita, K., Asha, D., Baquee, A.A., 2020. Formulation and Evaluation of Transdermal
706 Topical Gel of Ibuprofen. *J. Drug Deliv. Ther.* 10, 20–25.

707 Aodah, A.H., Bakr, A.A., Booq, R.Y., Rahman, M.J., Alzahrani, D.A., Alsulami, K.A.,
708 Alshaya, H.A., Alsuabeyl, M.S., Alyamani, E.J., Tawfik, E.A., 2021. Preparation and
709 evaluation of benzalkonium chloride hand sanitizer as a potential alternative for alcohol-
710 based hand gels. *Saudi Pharm. J.* <https://doi.org/10.1016/j.jsps.2021.06.002>

711 Badie, H., Abbas, H., 2018. Novel Small Self-Assembled Resveratrol -Bearing Cubosomes
712 and Hexosomes: Preparation, Characterization and Ex Vivo Permeation. *Drug Dev.*
713 *Ind. Pharm.* <https://doi.org/10.1080/03639045.2018.1508220>

714 Bagde, A., Patel, K., Kutlehria, S., Chowdhury, N., Singh, M., 2019. Formulation of topical
715 ibuprofen solid lipid nanoparticle (SLN) gel using hot melt extrusion technique (HME)
716 and determining its anti-inflammatory strength. *Drug Deliv. Transl. Res.*
717 <https://doi.org/10.1007/s13346-019-00632-3>

718 Bera, H., Gaini, C., Kumar, S., Sarkar, S., Boddupalli, S., Ippagunta, S.R., 2016. HPMC-
719 based gastroretentive dual working matrices coated with Ca²⁺ ion crosslinked alginate-
720 fenugreek gum gel membrane. *Mater. Sci. Eng. C* 67, 170–181.
721 <https://doi.org/10.1016/j.msec.2016.05.016>

722 Berth-Jones, J., Goh, C.L., Maibach, H.I., 2020. Updates in Clinical Dermatology: Rosacea.
723 Springer Nature Switzerland, USA.

724 Berthet, A., Oltramare, C., Spring, P., Hechon, J., Hopf, N.B., 2020. Human skin permeation

725 rates ex vivo following exposures to mixtures of glycol ethers. *Toxicol. Lett.* 335, 1–10.
726 <https://doi.org/10.1016/j.toxlet.2020.09.017>

727 Bertoni, S., Tedesco, D., Bartolini, M., Prata, C., Passerini, N., Albertini, B., 2020. Solid
728 Lipid Microparticles for Oral Delivery of Catalase: Focus on the Protein Structural
729 Integrity and Gastric Protection. *Mol. Pharm.* 17, 3609–3621.
730 <https://doi.org/10.1021/acs.molpharmaceut.0c00666>

731 Ceruelos, A.H., Romero-Quezada, L.C., Ruvalcaba Ledezma, J.C., López Contreras, L.,
732 2019. Therapeutic uses of metronidazole and its side effects: An update. *Eur. Rev. Med.*
733 *Pharmacol. Sci.* 23, 397–401. https://doi.org/10.26355/eurrev_201901_16788

734 Das, B., Nayak, A.K., Nanda, U., 2013. Topical gels of lidocaine HCl using cashew gum and
735 Carbopol 940: Preparation and in vitro skin permeation. *Int. J. Biol. Macromol.* 62, 514–
736 517. <https://doi.org/10.1016/j.ijbiomac.2013.09.049>

737 de Araújo, J.S.M., Volpato, M.C., Muniz, B.V., Xavier, G.G.A., Martinelli, C.C.M., Lopez,
738 R.F.V., Groppo, F.C., Franz-Montan, M., 2021. Resistivity Technique for the Evaluation
739 of the Integrity of Buccal and Esophageal Epithelium Mucosa for In Vitro Permeation
740 Studies : Swine Buccal and Esophageal Mucosa Barrier Models. *Pharmaceutics* 13, 1–
741 13.

742 De Caro, V., Giannola, L.I., Di Prima, G., 2021. Solid and semisolid innovative formulations
743 containing miconazole-loaded solid lipid microparticles to promote drug entrapment into
744 the buccal mucosa. *Pharmaceutics* 13, 1–21.
745 <https://doi.org/10.3390/pharmaceutics13091361>

746 Dolatabadi, J.E.N., Valizadeh, H., Hamishehkar, H., 2015. Solid lipid nanoparticles as
747 efficient drug and gene delivery systems: Recent breakthroughs. *Adv. Pharm. Bull.* 5,
748 151–159. <https://doi.org/10.15171/apb.2015.022>

749 Dudhipala, N., Gorre, T., 2020. Neuroprotective effect of ropinirole lipid nanoparticles
750 enriched hydrogel for parkinson’s disease: In vitro, ex vivo, pharmacokinetic and
751 pharmacodynamic evaluation. *Pharmaceutics* 12, 1–24.
752 <https://doi.org/10.3390/pharmaceutics12050448>

753 El-Housiny, S., Eldeen, M.A.S., El-Attar, Y.A., Salem, H.A., Attia, D., Bendas, E.R., El-
754 Nabarawi, M.A., 2018. Fluconazole-loaded solid lipid nanoparticles topical gel for
755 treatment of pityriasis versicolor: Formulation and clinical study. *Drug Deliv.* 25, 78–90.
756 <https://doi.org/10.1080/10717544.2017.1413444>

757 El-kamel, A.H., Al-fagih, I.M., Alsarra, I.A., 2007. Testosterone solid lipid microparticles for
758 transdermal drug delivery . Formulation and physicochemical characterization. *J.*
759 *Microencapsul.* 24, 457–475. <https://doi.org/10.1080/02652040701368865>

760 El-say, K.M., Hosny, K.M., 2018. Optimization of carvedilol solid lipid nanoparticles : An
761 approach to control the release and enhance the oral bioavailability on rabbits. *PLoS*
762 *One* 1–15.

763 Elmas, A., Akyüz, G., Bergal, A., Andaç, M., Andaç, Ö., 2020. Mathematical modelling of
764 drug release. *Res. Eng. Struct. Mater.* 6, 327–350.
765 <https://doi.org/10.17515/resm2020.178na0122>

766 Enggi, C.K., Isa, H.T., Sulistiawati, S., Ardika, K.A.R., Wijaya, S., Asri, R.M., Mardikasari,
767 S.A., Donnelly, R.F., Permana, A.D., 2021. Development of thermosensitive and
768 mucoadhesive gels of cabotegravir for enhanced permeation and retention profiles in
769 vaginal tissue: A proof of concept study. *Int. J. Pharm.* 609, 121182.
770 <https://doi.org/10.1016/j.ijpharm.2021.121182>

771 Engin, B., Çiğdem, M., Oba, Ç., Kutlubay, Z., 2017. Acne Rosacea, in: *Acne and Acneiform*
772 *Eruptions.* pp. 183–193. <https://doi.org/http://dx.doi.org/10.5772/65636>

773 Ghaderi, S., Ghanbarzadeh, S., Mohammadhassani, Z., Hamishehkar, H., 2014. Formulation
774 of Gammaoryzanol-Loaded Nanoparticles for Potential Application in Fortifying Food

775 Products. *Adv. Pharm. Bull.* 4, 549–554. <https://doi.org/10.5681/apb.2014.081>

776 Gonçalves, M.M.B.D.M.M., De Pina, M.E.S.R.T., 2017. Dermocosmetic care for rosacea.
777 *Brazilian J. Pharm. Sci.* 53, 1–16. <https://doi.org/10.1590/s2175-97902017000400182>

778 Güllü, H., Nuaimi, M.M.D. Al, AYTEK, A., 2020. Rheological and strength performances of
779 cold-bonded geopolymer made from limestone dust and bottom ash for grouting and
780 deep mixing. *Bull. Eng. Geol. Environ.*

781 Hajariwala, N.R., Chandrakar, V.R., Lakhani, J.D., 2021. Peripheral Neuropathy : A Rare
782 Side Effect of Metronidazole. *J. Integr. Heal. Sci.* 83–85.
783 <https://doi.org/10.4103/JIHS.JIHS>

784 Helal, H.M., Mortada, S.M., Sallam, M.A., 2016. Paliperidone-Loaded Nanolipomer System
785 for Sustained Delivery and Enhanced Intestinal Permeation : Superiority to Polymeric
786 and Solid Lipid Nanoparticles. *AAPS PharmSciTech.* <https://doi.org/10.1208/s12249-016-0657-1>

788 Himawan, A., Djide, N.J.N., Mardikasari, S.A., Utami, R.N., Arjuna, A., Donnelly, R.F.,
789 Permana, A.D., 2022. A novel in vitro approach to investigate the effect of food intake
790 on release profile of valsartan in solid dispersion-floating gel in-situ delivery system.
791 *Eur. J. Pharm. Sci.* 168, 106057. <https://doi.org/10.1016/j.ejps.2021.106057>

792 Ignjatović, J., Đuriš, J., Cvijić, S., Dobričić, V., Montepietra, A., Lombardi, C., Ibrić, S.,
793 Rossic, A., A, 2021. Development of solid lipid microparticles by melt-
794 emulsification/spray- drying processes as carriers for pulmonary drug delivery. *Eur. J.*
795 *Pharm. Sci.* 156.

796 Jabbehdari, S., Memar, O.M., Caughlin, B., Djalilian, A.R., 2021. Update on the
797 pathogenesis and management of ocular rosacea: an interdisciplinary review *Sayena.*
798 *Eur. J. Ophthalmol.* 31, 22–33. <https://doi.org/10.1177/1120672120937252>

799 Jaspert, S., Pascal, B., Piel, G., Dogne, J.-M., Delattre, L., Evrard, B., 2007. Solid lipid
800 microparticles as a sustained release system for pulmonary drug delivery. *Eur. J. Pharm.*
801 *Biopharm.* 65, 47–56. <https://doi.org/10.1016/j.ejpb.2006.07.006>

802 Kakkar, V., Kaur, I.P., Kaur, A.P., Saini, K., Singh, K.K., 2018. Topical delivery of
803 tetrahydrocurcumin lipid nanoparticles effectively inhibits skin inflammation: in vitro
804 and in vivo study. *Drug Dev. Ind. Pharm.*
805 <https://doi.org/10.1080/03639045.2018.1492607>

806 Kaur, L.P., Guleri, T.K., 2013. Topical Gel: A Recent Approach for Novel Drug delivery.
807 *Asian J. Biomed. Pharm. Sci.* 3, 1–5.

808 Kaur, R., Ajitha, M., 2019. Formulation of transdermal nanoemulsion gel drug delivery
809 system of lovastatin and its in vivo characterization in glucocorticoid induced
810 osteoporosis rat model. *J. Drug Deliv. Sci. Technol.*
811 <https://doi.org/10.1016/j.jddst.2019.06.008>

812 Kazemi, D., Salouti, M., Rostamizadeh, K., Zabihian, A., 2014. Development of Gentamicin-
813 loaded Solid lipid Nanoparticles : Evaluation of Drug Release Kinetic and Antibacterial
814 activity against *Staphylococcus aureus* Development of Gentamicin-loaded Solid lipid
815 Nanoparticles : Evaluation of Drug Release Kinetic and An. *Int. J. Pharm. Res. Innov.* 7,
816 1–6.

817 Kenechukwu, F.C., Attama, A.A., Ibezim, E.C., Nnamani, P.O., Umeyor, C.E., Uronnachi,
818 E.M., Gugu, T.H., Momoh, M.A., Ofokansi, K.C., Akpa, P.A., 2017. Surface-modified
819 mucoadhesive microgels as a controlled release system for miconazole nitrate to
820 improve localized treatment of vulvovaginal candidiasis. *Eur. J. Pharm. Sci.*
821 <https://doi.org/10.1016/j.ejps.2017.10.002>

822 Khurana, B., Arora, D., Narang, R.K., 2020. QbD based exploration of resveratrol loaded
823 polymeric micelles based carbomer gel for topical treatment of plaque psoriasis: In vitro,
824 ex vivo and in vivo studies. *J. Drug Deliv. Sci. Technol.*

825 <https://doi.org/10.1016/j.jddst.2020.101901>

826 Khurana, S., Jain, N.K., Bedi, P.M.S., 2013. Development and characterization of a novel
827 controlled release drug delivery system based on nanostructured lipid carriers gel for
828 meloxicam. *Life Sci.* 93, 763–772. <https://doi.org/10.1016/j.lfs.2013.09.027>

829 Lambers, H., Piessens, S., Bloem, A., Pronk, H., Finkel, P., 2006. Natural skin surface pH is
830 on average below 5 , which is beneficial for its resident flora Natural skin surface pH is
831 on average below 5 , which is beneficial for its resident flora. *Int. J. Cosmet. Sci.* 28,
832 359–370. <https://doi.org/10.1111/j.1467-2494.2006.00344.x>

833 López- Iglesias, C., Barros, J., Ardao, I., Gurikov, P., Monteiro, F.J., Smirnova, I., Alvarez-
834 Lorenzo, Carmen García- González, C.A., 2020. Jet Cutting Technique for the
835 Production of Chitosan Aerogel Microparticles Loaded with Vancomycin. *Polymers*
836 (Basel). 12, 1–13.

837 Luki, M., Pantelić, I., Savić, S.D., 2021. Towards Optimal pH of the Skin and Topical
838 Formulations : From the Current State of the Art to Tailored Products. *Cosmetics* 8.

839 Lv, Y., He, Haisheng, Qi, Jianping, Lu, Yi, Zhao, Weili, Dong, Xiaochun, He, H, Qi, J, Lu,
840 Y, Zhao, W, Dong, X, Wu, W., 2018. Visual validation of the measurement of
841 entrapment efficiency of. *Int. J. Pharm.* <https://doi.org/10.1016/j.ijpharm.2018.06.025>

842 Mahajan, H.S., Tyagi, V., Lohiya, G., Nerkar, P., 2012. Thermally reversible xyloglucan gels
843 as vehicles for Th nasal drug delivery. *Drug Deliv.* 19, 270–276.
844 <https://doi.org/10.3109/10717544.2012.704095>

845 Malik, D.S., Kaur, G., 2018. Nanostructured gel for topical delivery of azelaic acid:
846 Designing, characterization, and in-vitro evaluation. *J. Drug Deliv. Sci. Technol.* 47,
847 123–136.

848 Mandawgade, S.D., Patravale, V.B., 2008. Development of SLNs from natural lipids:
849 Application to topical delivery of tretinoin. *Int. J. Pharm.* 363, 132–138.
850 <https://doi.org/10.1016/j.ijpharm.2008.06.028>

851 Mirchandani, Y., Patravale, V.B., Brijesh, S., 2021. Solid lipid nanoparticles for hydrophilic
852 drugs. *J. Control. Release* 335, 457–464. <https://doi.org/10.1016/j.jconrel.2021.05.032>

853 Miyachi, Y., 2001. Potential antioxidant mechanism of action for metronidazole:
854 Implications for rosacea management. *Adv. Ther.* 18, 237–243.
855 <https://doi.org/10.1007/BF02850193>

856 Miyachi, Y., Yamasaki, K., Fujita, T., Fujii, C., 2022. Metronidazole gel (0 . 75 %) in
857 Japanese patients with rosacea : A randomized , vehicle- - controlled , phase 3 study. *J.*
858 *Dermatology* 49, 330–340. <https://doi.org/10.1111/1346-8138.16254>

859 Morsi, N., Ibrahim, M., Refai, H., El Sorogy, H., 2017. Nanoemulsion-based electrolyte
860 triggered in situ gel for ocular delivery of acetazolamide. *Eur. J. Pharm. Sci.* 104, 302–
861 314. <https://doi.org/10.1016/j.ejps.2017.04.013>

862 Mu, H., Holm, R., 2018. Solid lipid nanocarriers in drug delivery: characterization and
863 design. *Expert Opin. Drug Deliv.* <https://doi.org/10.1080/17425247.2018.1504018>

864 Nabi-Meibodi, M., Navidi, B., Navidi, N., Vatanara, A., Reza Rouini, M., Ramezani, V.,
865 2013. Optimized double emulsion-solvent evaporation process for production of solid
866 lipid nanoparticles containing baclofene as a lipid insoluble drug. *J. Drug Deliv. Sci.*
867 *Technol.* 23, 225–230. [https://doi.org/10.1016/S1773-2247\(13\)50034-7](https://doi.org/10.1016/S1773-2247(13)50034-7)

868 Nahum, V., Domb, A.J., 2021. Recent developments in solid lipid microparticles for food
869 ingredients delivery. *Foods* 10, 1–25. <https://doi.org/10.3390/foods10020400>

870 Neupane, R., Boddu, S.H.S., Renukuntla, J., Babu, R.J., 2020. Alternatives to Biological Skin
871 in Permeation Studies : Current Trends and Possibilities. *Pharmaceutics* 12.

872 Ojha, B., Kumar, V., Surabhi, J., Sushama, G., 2021. Nanoemulgel : a promising novel
873 formulation for treatment of skin ailments. *Polym. Bull.* [https://doi.org/10.1007/s00289-](https://doi.org/10.1007/s00289-021-03729-3)
874 021-03729-3

875 Ontong, J.C., Singh, S., Nwabor, O.F., Chusri, S., Voravuthikunchai, S.P., 2020. Potential of
876 antimicrobial topical gel with synthesized biogenic silver nanoparticle using
877 *Rhodomyrtus tomentosa* leaf extract and silk sericin. *Biotechnol. Lett.*
878 <https://doi.org/10.1007/s10529-020-02971-5>

879 Oriani, V.B., Alvim, I.D., Consoli, L., Molina, G., Pastore, G.M., Hubinger, M.D., 2016.
880 Solid lipid microparticles produced by spray chilling technique to deliver ginger
881 oleoresin: Structure and compound retention. *Food Res. Int.* 80, 41–49.
882 <https://doi.org/10.1016/j.foodres.2015.12.015>

883 Parmar, B., Mandal, S.A., Petkar, K.C., Patel, L.D., Sawant, K.K., 2011. Valsartan Loaded
884 Solid Lipid Nanoparticles: Development, Characterization, and In vitro and Ex vivo
885 Evaluation. *Int. J. Pharm. Sci. Nanotechnol.* 4, 1483–1490.
886 <https://doi.org/10.37285/ijpsn.2011.4.3.7>

887 Patel, J., Patel, B., Banwit, H., Parmar, K., Patel, M., 2011. Formulation And Evaluation of
888 Topical Aceclofenac Gel Using Different Gelling Agent. *Int. J. Drug Dev. Res.* 3, 156–
889 164.

890 Patil, P.B., Datir, S.K., Saudagar, R.B., 2019. A Review on Topical Gels as Drug Delivery
891 System. *J. Drug Deliv. Ther.* 9, 989–994.

892 Permana, A.D., Anjani, Q.K., Sartini, Utomo, E., Volpe-Zanutto, F., Paredes, A.J., Evary,
893 Y.M., Mardikasari, S.A., Pratama, M.R., Tuany, I.N., Donnelly, R.F., 2021a. Selective
894 delivery of silver nanoparticles for improved treatment of biofilm skin infection using
895 bacteria-responsive microparticles loaded into dissolving microneedles. *Mater. Sci. Eng.*
896 *C* 120, 111786.

897 Permana, A.D., Paredes, A.J., Volpe-Zanutto, F., Anjani, Q.K., Utomo, E., Donnelly, R.F.,
898 2020a. Dissolving microneedle-mediated dermal delivery of itraconazole nanocrystals
899 for improved treatment of cutaneous candidiasis. *Eur. J. Pharm. Biopharm.* 154, 50–61.
900 <https://doi.org/10.1016/j.ejpb.2020.06.025>

901 Permana, A.D., Tekko, I.A., McCrudden, M.T.C., Anjani, Q.K., Ramadon, D., McCarthy,
902 H.O., Donnelly, R.F., 2019. Solid lipid nanoparticle-based dissolving microneedles: A
903 promising intradermal lymph targeting drug delivery system with potential for enhanced
904 treatment of lymphatic filariasis. *J. Control. Release* 316, 34–52.

905 Permana, A.D., Utami, R.N., Courtenay, A.J., Manggau, M.A., Donnelly, R.F., Rahman, L.,
906 2020b. Phytosomal nanocarriers as platforms for improved delivery of natural
907 antioxidant and photoprotective compounds in propolis: An approach for enhanced both
908 dissolution behaviour in biorelevant media and skin retention profiles. *J. Photochem.*
909 *Photobiol. B Biol.* <https://doi.org/10.1016/j.jphotobiol.2020.111846>

910 Permana, A.D., Utomo, E., Pratama, M.R., Amir, M.N., Anjani, Q.K., Mardikasari, S.A.,
911 Sumarheni, S., Himawan, A., Arjuna, A., Usmanengsi, U., Donnelly, R.F., 2021b.
912 Bioadhesive-Thermosensitive in Situ Vaginal Gel of the Gel Flake-Solid Dispersion of
913 Itraconazole for Enhanced Antifungal Activity in the Treatment of Vaginal Candidiasis.
914 *ACS Appl. Mater. Interfaces* 13, 18128–18141. <https://doi.org/10.1021/acsami.1c03422>

915 Priyanka, N.V.S.A.I., Neeraja, P., Mangilal, T., Kumar, M.R., 2019. Formulation and
916 Evaluation of Gel Loaded with Microspheres of Apremilast for Transdermal Delivery
917 System. *Asian J. Pharm. Clin. Res.* 12. <https://doi.org/10.22159/ajpcr.2019.v12i2.29374>

918 Rabima, R., Sari, M.P., 2019. Entrapment efficiency and drug loading of curcumin
919 nanostructured lipid carrier (NLC) formula. *Pharmaciana* 9, 299–306.
920 <https://doi.org/10.12928/pharmaciana.v9i2.13070>

921 Rahimpour, Y., Javadzadeh, Y., Hamishehkar, H., 2016. Solid lipid microparticles for
922 enhanced dermal delivery of tetracycline HCl. *Colloids Surfaces B Biointerfaces* 145,
923 14–20. <https://doi.org/10.1016/j.colsurfb.2016.04.034>

924 Rahmawati, D.A., Setiawan, I., 2019. The Formulation and Physical Stability Test Of Gel

925 Fruit Strawberry Extract (*Fragaria x ananassa* Duch .). *J. Nutraceuticals Herb. Med.* 2,
926 38–46.

927 Rainer, B.M., Thompson, K.G., Antonescu, C., Florea, L., Mongodin, E.F., Bui, J., Fischer,
928 A.H., Pasioka, H.B., Garza, L.A., Kang, S., Chien, A.L., 2019. Characterization and
929 Analysis of the Skin Microbiota in Rosacea : A Case – Control Study. *Am. J. Clin.*
930 *Dermatol.* <https://doi.org/10.1007/s40257-019-00471-5>

931 Rajan, R., Vasudevan, D.T., 2012. Effect of permeation enhancers on the penetration
932 mechanism of transfersomal gel of ketoconazole. *J. Adv. Pharm. Tech. Res.* 3.
933 <https://doi.org/10.4103/2231-4040.97286>

934 Rowe, R.C., Sheskey, P.J., Quinn, M., 2009. *Handbook of Pharmaceutical Excipients* 6th
935 Edition. Pharmaceutical Press and American Pharmacists Association, London.

936 Safitri, I., Nawangsari, D., Febrina, D., 2021. Overview : Application of Carbopol 940 in Gel.
937 *Adv. Heal. Sci. Res.* 34, 80–84.

938 Shi, L., Li, Z., Yu, L., Jia, H., Zheng, L., 2011. Effects of surfactants and lipids on the
939 preparation of solid lipid nanoparticles using double emulsion method. *J. Dispers. Sci.*
940 *Technol.* 32, 254–259. <https://doi.org/10.1080/01932691003659130>

941 Shinde, U.A., Parmar, S.J., Easwaran, S., 2019. Metronidazole-loaded nanostructured lipid
942 carriers to improve skin deposition and retention in the treatment of rosacea. *Drug Dev.*
943 *Ind. Pharm.* <https://doi.org/10.1080/03639045.2019.1569026>

944 Singh, V.K., Singh, P.K., Sharma, P.K., Srivastava, P.K., Mishra, A., 2013. Formulation and
945 Evaluation of Topical Gel of Acetofenac Containing Piparine. *Indo Am. J.*
946 *PPharmaceutical Res.*

947 Soute, E.B., Müller, R.H., 2007. Lipid Nanoparticles (Solid Lipid Nanoparticles and
948 Nanostructured Lipid Carriers) for Cosmetic, Dermal, and Transdermal Applications, in:
949 *Nanoparticulate Drug-Delivery Systems.* pp. 213–229.

950 Sulistiawati, Enggi, C.K., Isa, H.T., Wijaya, S., Ardika, K.A.R., Asri, R.M., Donnelly, R.F.,
951 Permana, A.D., 2021. Validation of spectrophotometric method to quantify cabotegravir
952 in simulated vaginal fluid and porcine vaginal tissue in ex vivo permeation and retention
953 studies from thermosensitive and mucoadhesive gels. *Spectrochim. Acta - Part A Mol.*
954 *Biomol. Spectrosc.* 267. <https://doi.org/10.1016/j.saa.2021.120600>

955 Thakkar, R., Jara, M.O., Swinnea, S., Pillai, A.R., Maniruzzaman, M., 2021. Impact of laser
956 speed and drug particle size on selective laser sintering 3d printing of amorphous solid
957 dispersions. *Pharmaceutics* 13, 1–19. <https://doi.org/10.3390/pharmaceutics13081149>

958 Tran, M.L., Fu, C.C., Juang, R.S., 2019. Effects of water matrix components on degradation
959 efficiency and pathways of antibiotic metronidazole by UV/TiO₂ photocatalysis. *J. Mol.*
960 *Liq.* <https://doi.org/10.1016/j.molliq.2018.11.155>

961 van Zuuren, E.J., Arents, B.W.M., van der Linden, M.M.D., Vermeulen, S., Fedorowicz, Z.,
962 Tan, J., 2021. Rosacea: New Concepts in Classification and Treatment. *Am. J. Clin.*
963 *Dermatol.* 22, 457–465. <https://doi.org/10.1007/s40257-021-00595-7>




964 Weiss, E., Katta, R., 2017. Diet and rosacea: the role of dietary change in the management of
965 rosacea. *Dermatol. Pract. Concept.* 7, 31–37. <https://doi.org/10.5826/dpc.0704a08>

966 Wolska, E., Brach, M., 2022. Distribution of Drug Substances in Solid Lipid Microparticles
967 (SLM)—Methods of Analysis and Interpretation. *Pharmaceutics* 14, 1–18.
968 <https://doi.org/10.3390/pharmaceutics14020335>

969 Yen, W.F., Basri, M., Ahmad, M., Ismail, M., 2015. Formulation and Evaluation of
970 Galantamine Gel as Drug Reservoir in Transdermal Patch Delivery System. *Sci. World*
971 *J.* 1–7.

972 Yu, M., Ma, H., Lei, M., Li, N., Tan, F., 2014. In vitro / in vivo characterization of
973 nanoemulsion formulation of metronidazole with improved skin targeting and anti-
974 rosacea properties. *Eur. J. Pharm. Biopharm.* <https://doi.org/10.1016/j.ejpb.2014.03.019>

975 Zhang, H., Tang, K., Wang, Y., Fang, R., 2021. Rosacea Treatment : Review and Update.
976 Dermatol. Ther. (Heidelb). 11, 13–24. <https://doi.org/10.1007/s13555-020-00461-0>
977 Zhang, L., Huang, T., Bi, J., Zheng, Y., Lu, C., Hui, Q., 2020. Long-Term Toxicity Study of
978 Topical Administration of a Highly-Stable rh-aFGF Carbomer 940 Hydrogel in a Rabbit
979 Skin Wound Model 11, 1–8. <https://doi.org/10.3389/fphar.2020.00058>
980 Zhang, S., Fang, M., Zhang, Q., Li, X., Zhang, T., 2019. Evaluating the Bioequivalence of
981 Metronidazole Tablets and Analyzing the Effect of in Vitro Dissolution on in Vivo
982 Absorption Based on PBPK Modeling. Drug Dev. Ind. Pharm.
983 <https://doi.org/10.1080/03639045.2019.1648502>
984 Zhang, Y., Huo, M., Zhou, J., Zou, A., Li, W., Yao, C., Xie, S., 2010. DDSolver: An add-in
985 program for modeling and comparison of drug dissolution profiles. AAPS J. 12, 263–
986 271.
987



Solid lipid microparticles formulation

Enhanced skin retention profiles



MINISTRY OF EDUCATION CULTURE OF INDONESIA
HASANUDDIN UNIVERSITY
FACULTY OF PHARMACY

Alamat Jalan Perintis kemerdekaan Km.10, Makassar 90245
Telepon (0411) 588556, Faksimili (0411) 590663
Laman: farmasi@unhas.ac.id

The Editor
International Journal of Pharmaceutics

October 16, 2022

Dear Sir/Madam,

I wish you to re-consider our manuscript entitled “Enhanced skin localization of metronidazole using solid lipid microparticles incorporated into polymeric hydrogels for potential improved of rosacea treatment” for publication in *International Journal of Pharmaceutics*. As we have revised our manuscript based on comments from reviewers, we changed our title to “Enhanced skin localization of metronidazole using solid lipid microparticles incorporated into polymeric hydrogels for potential improved of rosacea treatment: An *ex vivo* proof of concept investigation”

We have made some changes to the manuscript as a result of the comments from the reviewer. We believe that the manuscript is now substantially improved. We have addressed each of the reviewers’ comments in the response to the reviewer file. Importantly, we have made a great effort to improve the English and the discussion parts of our revised manuscript.

This manuscript has not been previously published in any language anywhere and that it is not under simultaneous consideration by another journal. We appreciate your attention. We hope you will now consider publishing our research in *International Journal of Pharmaceutics* and look forward to hearing from you in due course.

Yours Sincerely,

Andi Dian Permana (on behalf of all authors)
Faculty of Pharmacy
Hasanuddin University
Indonesia
Email: andi.dian.permana@farmasi.unhas.ac.id

Ms. Ref. No.: IJPHARM-D-22-02381

Title: Enhanced skin localization of metronidazole using solid lipid microparticles incorporated into polymeric hydrogels for potential improved of rosacea treatment

International Journal of Pharmaceutics

Reviewer #1: Dear respected editor

The manuscript entitled "Enhanced skin localization of metronidazole using solid lipid 1 microparticles incorporated into polymeric hydrogels for potential improved of rosacea treatment" described the preparation and characterization of metronidazole loaded solid lipid microparticles.

The manuscript is interesting; however several points should be considered for accepting the manuscript.

Response to Reviewer

We are very thankful to the Reviewer for taking the time to review this manuscript and for the expert review, providing helpful comments. We are glad that the Reviewer thinks that our work is interesting. We have made a number of key changes to the manuscript as a result of these comments. We believe that the manuscript is now substantially improved. We have addressed each one of the reviewers' comments in detail.

Minor points are listed below:

1- First of all the manuscript should be checked by an English native speaker to remove the syntax and typos; in addition some sentences are very long

Response:

We are very thankful to the expert reviewers for the suggestions. We have re-read the manuscript and have made a great effort to improve the English throughout. We believe that the manuscript is now substantially improved

2- One of the major shortcomings of the manuscript is that it does not refer in the introduction part such literature data in which metronidazole have been formulated topically using different delivery systems to treat rosacea.

Response:

We thank the reviewer for the suggestion. Several approaches have been developed to improve the skin delivery of MNZ, including nanostructured lipid carrier ¹ and nanoemulsion ². However, despite the fact that the formulations could improve the transdermal delivery of MNZ, in the rosacea treatment, it is crucial to retain the drug in the skin layers. It has been previously reported that compared to nanoparticles, microparticle systems possessed better skin retention profiles. Accordingly, it was hypothesized that the incorporation of MNZ into the microparticle system could improve the skin retention of MNZ. We have included these in the revised manuscript.

3- The novelty of the work should be clearly stated, other articles with similar work had been published: "Metronidazole-loaded nanostructured lipid carriers to improve skin deposition and retention in the treatment of rosacea, Drug Dev Ind Pharm, 2019 Jul;45(7):1039-1051."

Response:

We thank the reviewer for the suggestion. It has been previously reported that compared to nanoparticles, microparticle systems possessed better skin retention profiles ³. Accordingly, it was hypothesized that the incorporation of MNZ into the microparticle system could improve the skin retention of MNZ. We have included these in the revised manuscript.

4- SLMs containing metronidazole had been prepared using other methods of preparation, The authors should justify the choice of this method used in the preparation of SLMs

Response:

We thank the reviewer for the comment. In this study, MNZ-loaded SLM was prepared using the double emulsification method. MNZ is a hydrophilic drug ¹. The double emulsification method has become one of the ideal methods in the preparation of SLM containing hydrophilic drugs. This is evidenced by several previous studies that have been described by Mirchandani et al. (2021). Multiple emulsion systems (water-in-oil-in-water, w/o/w) can provide better entrapment

of hydrophilic drugs ⁵. In addition, SLM prepared by this method can avoid the partition of hydrophilic drugs that are released from the oil phase to the outer phase (water) during the emulsification process.

5- How did the authors measure the entrapment efficiency without separating the free drug?

Response:

We thank the reviewer for pointing this out. In the preparation of SLMs, to produce concentrated SLMs and separate free MNZ from the SLMs, the formulation was centrifuged at 5,000 rpm for 30 min using an Amicon[®] Ultra Centrifugal Device (Millipore Inc, molecular weight cut-off (MWCO) of 12 kDa). We have included this in the revised manuscript.

6- What is the ratio of SLMs to gel used to obtain the final preparation?

Response:

We thank the reviewer for the question. In this study, we used the ratio of 1.28% of SLM for each 100% part of the hydrogel. The selection of 1.28% was based on the drug loading and encapsulation efficiency to achieve a final concentration of 1% MNZ in the hydrogel formulation.

7- Please correct the decimal of the numbers in Table 1, and add asterisk symbol to show the significance

Response:

We thank the reviewer for the suggestion. We have corrected these in the revised manuscript.

8- Figure 4 should be corrected by drawing the shear rate on the x axis and the shear stress on the y axis

Response:

We thank the reviewer for the suggestion. We have corrected these in the revised manuscript.

Major point

It is regrettable that the authors do not carry out in vitro and in vivo study to test the antioxidant effect, anti-inflammatory effect and the safety of the prepared formula, especially there are organic solvent included in the preparation.

Response:

We thank the reviewer for pointing this out. In this study, we focused on an ex vivo proof of concept study, concerning the ability of the combination of SLM and hydrogel to localize MNZ in the skin. To clarify this, we have changed our title in the revised manuscript. Importantly, we have performed antioxidant activity as an initial assesment. In the clinical manifestations of rosacea, free radicals have been found to play an important role in extrinsic and intrinsic aging. The reactive oxygen species produced by neutrophiles can lead to damage to oxidative tissue ⁶. Accordingly, in this study, we evaluated the antioxidant activity of MNZ. In DPPH evaluations, the IC50 values of free drug, SLM, F1, F2, F3 and F4 were found to be $103.88 \pm 9.34 \mu\text{g/mL}$, $109.11 \pm 10.02 \mu\text{g/mL}$, $102.65 \pm 8.08 \mu\text{g/mL}$, $112.43 \pm 11.31 \mu\text{g/mL}$, $106.42 \pm 11.05 \mu\text{g/mL}$ and $107.17 \pm 9.87 \mu\text{g/mL}$, respectively. Furthermore, in the lipid peroxidation method, the IC50 values were $121.03 \pm 11.31 \mu\text{g/mL}$ for free drug, $126.03 \pm 11.98 \mu\text{g/mL}$ for SLM, $131.45 \pm 12.01 \mu\text{g/mL}$ for F1, $126.98 \pm 12.01 \mu\text{g/mL}$ for F2, $131.22 \pm 12.15 \mu\text{g/mL}$ for F3 and $127.87 \pm 11.81 \mu\text{g/mL}$ for F4. In both methods, there were no significant differences ($p > 0.05$) in the IC50 values, indicating that the formulation of MNZ into SLM and hydrogel did not affect the antioxidant properties of MNZ.

References:

- (1) Shinde, U. A.; Parmar, S. J.; Easwaran, S. Metronidazole-Loaded Nanostructured Lipid Carriers to Improve Skin Deposition and Retention in the Treatment of Rosacea. *Drug Dev. Ind. Pharm.* **2019**. <https://doi.org/10.1080/03639045.2019.1569026>.
- (2) Yu, M.; Ma, H.; Lei, M.; Li, N.; Tan, F. In Vitro / in Vivo Characterization of Nanoemulsion Formulation of Metronidazole with Improved Skin Targeting and Anti-Rosacea

- Properties. *Eur. J. Pharm. Biopharm.* **2014**. <https://doi.org/10.1016/j.ejpb.2014.03.019>.
- (3) Permana, A. D.; Anjani, Q. K.; Sartini; Utomo, E.; Volpe-Zanutto, F.; Paredes, A. J.; Evary, Y. M.; Mardikasari, S. A.; Pratama, M. R.; Tuany, I. N.; Donnelly, R. F. Selective Delivery of Silver Nanoparticles for Improved Treatment of Biofilm Skin Infection Using Bacteria-Responsive Microparticles Loaded into Dissolving Microneedles. *Mater. Sci. Eng. C* **2021**, *120* (October 2020), 111786.
- (4) Mirchandani, Y.; Patravale, V. B.; Brijesh, S. Solid Lipid Nanoparticles for Hydrophilic Drugs. *J. Control. Release* **2021**, *335* (February), 457–464.
<https://doi.org/10.1016/j.jconrel.2021.05.032>.
- (5) Akki, R.; Bhattiprolu, S. S.; Vinukonda, A.; Kathirvel, S. An Overview on Liposheres. *World J. Pharm. Res.* **2022**, *11* (8), 217–232. <https://doi.org/10.20959/wjpr20228-24470>.
- (6) Miyachi, Y. Potential Antioxidant Mechanism of Action for Metronidazole: Implications for Rosacea Management. *Adv. Ther.* **2001**, *18* (6), 237–243.
<https://doi.org/10.1007/BF02850193>.

CRedit authorship contribution statement

Sulistiawati: Conceptualization, Methodology, Funding acquisition, Writing – original draft. **Kadek Saka Dwipayanti:** Methodology, Writing – original draft. **Muhammad Azhar:** Methodology, Writing – original draft. **Latifah Rahman:** Methodology, Data curation. **Ermina Pakki:** Methodology, Data curation. **Achmad Himawan:** Data curation, Validation, Supervision **Andi Dian Permana:** Conceptualization, Project administration, Funding acquisition, Validation, Supervision, Writing – original draft.

BUKTI
ACCEPTED

Your Submission

1 message

International Journal of Pharmaceutics <em@editorialmanager.com>
Reply-To: International Journal of Pharmaceutics <support@elsevier.com>
To: Andi Dian Permana <andi.dian.permana@farmasi.unhas.ac.id>

Mon, Oct 17, 2022 at 5:26 PM

Ms. Ref. No.: IJPHARM-D-22-02381R1

Title: Enhanced skin localization of metronidazole using solid lipid microparticles incorporated into polymeric hydrogels for potential improved of rosacea treatment: An ex vivo proof of concept investigation
International Journal of Pharmaceutics

Dear Dr. Permana,

I am pleased to confirm that your paper Enhanced skin localization of metronidazole using solid lipid microparticles incorporated into polymeric hydrogels for potential improved of rosacea treatment: An ex vivo proof of concept investigation has been accepted for publication in International Journal of Pharmaceutics.

Upon transfer of your paper to our production department, your article proof will be created and sent to you for checking. You will also be asked to complete a number of online forms required for publication. If we need additional information from you during the production process, we will contact you.

Thank you for submitting your work to this journal.

IJP is the 2nd most cited journal in the category "Pharmacy & Pharmacology" (out of 279 journals) (Clarivate 2022).

IJPX is the open access companion journal of IJP. It received its first impact factor this year: 5.679.

Both journals are the true home for pharmaceutical scientists concerned with the physical, chemical and biological properties of devices and delivery systems for drugs, vaccines and biologicals, including their design, manufacture and evaluation.

We encourage authors of original research papers to share the research objects – including raw data, methods, protocols, software, hardware and other outputs – associated with their paper. More information on how our open access Research Elements journals can help you do this is available at https://www.elsevier.com/authors/tools-and-resources/research-elements-journals?dgcid=ec_em_research_elements_email.

With kind regards,

Abdul W Basit, PhD
Editor
International Journal of Pharmaceutics

#AU_IJPHARM#

To ensure this email reaches the intended recipient, please do not delete the above code

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/ijpharm/login.asp?a=r>). Please contact the publication office if you have any questions.



Andi Dian Permana <andi.dian.permana@farmasi.unhas.ac.id>

Dear Author, your article has been accepted

1 message

International Journal of Pharmaceutics <service@author.email.elsevier.com>

Fri, Oct 21, 2022 at 11:53 PM

Reply-To: no-reply <no-reply@author.email.elsevier.com>

To: andi.dian.permana@farmasi.unhas.ac.id

If you are unable to view this message correctly, [click here](#)



ELSEVIER

Congratulations on your accepted article!

Dear Author,

We recognize you have a choice of where to submit your research and we thank you for choosing to publish with *International Journal of Pharmaceutics*.

As an expert in the field, you are best placed to explain why your article, **Enhanced skin localization of metronidazole using solid lipid microparticles incorporated into polymeric hydrogels for potential improved of rosacea treatment: An ex vivo proof of concept investigation**, is interesting or impactful to a wider audience. Find out how you can help your article get the visibility it deserves:



Share and Publish your
Research Data



Researcher Academy



Get Noticed

We look forward to receiving future manuscripts from you!

Sincerely,

Researcher Engagement Team

Can we assist you with something? Visit our help page »

Elsevier supports responsible sharing:

Responsible sharing in line with copyright enables publishers to sustain high quality journals and the services they provide to the research community. [Find out how you can share your manuscript in Elsevier journals.](#)

- Find useful tools and resources: [Author Resources](#).
- For assistance, please visit our [Customer Support](#) site, where you can search for solutions on a range of topics and find answers to frequently asked questions.

Would you like to **update your information**? Amend your profile or publication history by visiting the [Scopus profile and content corrections Support Center](#).

If you do not wish to receive any further Service messages, please send us an [email](#).



This is a Service message, sent to you by Elsevier STM Journals.

Copyright © 2022 Elsevier Limited All rights reserved. | [Elsevier Privacy Policy](#)
Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB UK